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Abstract 
   
 
Branched-chain Amino Acids (BCAAs) are known to have positive effects in metabolic 
health through weight management and muscle protein synthesis. However, elevated 
levels of BCAAs (particularly leucine) and their metabolites have also been implicated in 
the development of insulin resistance and type 2 diabetes mellitus (T2DM). This study 
examines the dose-dependent effect of leucine in the presence or absence of other amino 
acids on glucose transport in L6 rat myotubes. Here we report that leucine significantly 
suppresses insulin-stimulated glucose uptake in skeletal muscle cells and particularly at 
150 µM, there is a 75% reduction in insulin-mediated glucose transport (p<0.01).  
This occurs in parallel with increased activation of proteins involved in the 
mammalian/mechanistic target of rapamycin complex 1 (mTORC1) pathway (p<0.05), 
which suggests a link between increased mTORC1 activity and insulin resistance. 
Interestingly, the suppressive effect of leucine on glucose transport disappears in the 
presence of other amino acids. We also illustrate that leucine’s metabolite, α-
ketoisocaproic acid (KIC) inhibits insulin-stimulated glucose uptake at 200 µM by 45% 
concurrent with increased activation of the mTORC1 pathway (p<0.05). Finally, siRNA 
knockdown of the branched-chain aminotransferase 2 mitochondrial (BCAT2) enzyme 
which catalyzes the reversible conversion of leucine to KIC, ameliorated the inhibitory 
effect of KIC on glucose transport (p<0.05), suggesting that the impairing effects of KIC 
on glucose transport occur through its conversion back to leucine. Taken together, our 
results show that in L6 myotubes, leucine and its metabolite significantly suppress 
insulin-mediated glucose transport. Moreover, modulating the activity of the BCAT2 
enzyme could be a new therapeutic approach in patients with high BCAA levels in 
conditions such obesity and T2DM.  
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1.0 Introduction 
 
      
     Diabetes is a major health concern in today’s world and its global burden is 
staggering. According to the International Diabetes Federation, approximately 1 in every 
12 people is diabetic with an estimated 387 million cases worldwide. Intriguingly, for 
every diabetic person, another person suffers from impaired glucose metabolism which 
increases their risk for other conditions such as heart disease and stroke 1.  
     T2DM accounts for about 90% of all cases of diabetes worldwide and its precursor is 
a condition known as insulin resistance which affects millions of people, particularly in 
Western societies2. It is one of the main causes of morbidity and mortality and a hallmark 
of chronic diseases such as obesity, T2DM, cardiovascular disease and metabolic 
syndrome.3,4 Nutrient overload is one of the main causes for the development of insulin 
resistance. Although high fat diets are generally considered to be the major cause of 
metabolic abnormalities, more recent evidence suggests that consumption of high protein 
diets is also associated with insulin resistance. 5–7 
     High protein diets are consistently used for weight management in obese individuals. 
They have been shown to have positive metabolic effects such as weight loss, increased 
basal metabolic rate, increased muscle mass and loss of fat mass.8–10 The underlying 
mechanisms for some of these positive effects are increased thermogenesis and prolonged 
feelings of satiety 10,11. It has been shown that BCAAs are the main components in high 
protein diets, which exert these beneficial effects. 6,8 Of the three BCAAs (leucine, 
isoleucine and valine), leucine has gained considerable attention due to its strong ability 
to activate mTORC1, the master regulator of cell growth, proliferation and protein 
synthesis. 12–15  
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     Despite their benefits, diets consisting of high levels of proteins have been shown to 
be implicated in the development of insulin resistance and T2DM.5,6,16 Increased 
circulating levels of BCAAs, specifically leucine, have been shown to be associated with 
hyperactivation of mTORC1, leading to the impairment of insulin signalling pathway and 
consequently the development of insulin resistance. In addition, elevated BCAA levels 
are frequently observed in human and rodent models of obesity 6,17.  Therefore, high 
protein/BCAA diets can act as a double-edged sword by demonstrating beneficial effects 
in the management of obesity while having the ability to negatively affect insulin 
sensitivity and ultimately cause insulin resistance and T2DM. 6  
     Since leucine is the most potent BCAA in activating the mTORC1 pathway 18,19, many 
studies have examined its effect on insulin signalling, however, current evidence is still 
inconclusive and many questions remain to be addressed. Moreover, the dose-dependent 
effect of leucine (within a range that is physiologically-relevant) on glucose transport and 
mTORC1 signalling has not yet been determined. In addition, since dietary protein 
contains amino acids other than BCAAs, it is essential to study the effect of a 
combination of amino acids on insulin signalling and mTORC1 pathway. It is also 
important to examine the mTORC1 pathway in response to specific metabolites of 
leucine, since the amino acid undergoes metabolic changes intracellularly that can affect 
the regulation of glucose transport and insulin signalling. Understanding the effect of 
leucine-mediated mTORC1 activation and glucose transport within skeletal muscle can 
be helpful in explaining the underlying mechanisms of BCAAs’ action in the 
development and progression of insulin resistance. This can ultimately help in the 
prevention and management of T2DM and reduce its burden.
  3 
2.0 Literature Review 
 
2.1 Insulin Signalling Within Skeletal Muscle 
 
     Skeletal muscle comprises about 40-50% of the adult human body weight 20,21. Thus, 
it is the most abundant insulin-sensitive tissue mediating about 85% of all insulin-
stimulated glucose disposal under normal physiological conditions. 21,22 In humans, 
insulin-stimulated glucose transport into skeletal muscle is the key mechanism through 
which disposal of ingested glucose occurs. Insulin-mediated glucose transport requires 
tightly regulated, multistep processes involving crosstalk with other signalling pathways.   
 
2.1.1 Insulin Receptor and Insulin Receptor Substrates    
    Upon binding to the insulin receptor (IR) on the sarcolemma of skeletal muscle, insulin 
increases the tyrosine kinase activity of insulin receptor. The insulin receptor is a member 
of the large tyrosine kinase family of transmembrane signaling receptors and plays an 
important role in metabolic regulation and glucose homeostasis. The receptor is 
composed of two extracellular α subunits, each connected to a β subunit and linked to 
each other by disulfide bonds forming a heterotetramer. 23 When endogenous ligands 
such as insulin and insulin-like growth factor 1 (IGF-1) bind the α subunits, they cause 
autophosphorylation of the β subunits exclusively on tyrosine residues.24 This tyrosine 
phosphorylation mediates the interaction of insulin with its receptors. Upon its activation, 
the insulin receptor phosphorylates other proteins such as the insulin receptor substrates 
1/2 (IRS-1, 2,3,4). The four members of the IRS family differ in their subcellular 
localization, tissue distribution and their ability to bind to insulin receptors. In fact, IRS-1 
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plays a major role in insulin signaling within skeletal muscle, while IRS-2 appears to 
regulate hepatic insulin action. 25 
     As a main substrate of the IR, IRS-1 plays a major role in transmitting insulin-
dependent signals that propagate many biological processes such as cell growth and 
cellular uptake of glucose. 26 IRS proteins are composed of an N-terminal region 
containing a pleckstrin homology (PH) domain and a phosphotyrosine-binding (PTP) 
domain that work together to ensure proper substrate phosphorylation by the activated IR. 
The C-terminal part of the IRS proteins contains various tyrosine phosphorylation motifs 
that act as docking sites for multiple signalling molecules that express Src homology-2 
(SH-2) binding domains such as phosphatidylinositol-3-kinase (PI3K), phosphotyrosine 
phosphatase (SHP-2), non-catalytic region of tyrosine kinase adaptor protein 1 (Nck1), 
chicken tumor virus number 10 regulator of kinase (Crk) and growth factor receptor-
bound protein 2 (Grb-2). 25,26 The PH domain of IRS-1 plays a critical role in promoting 
the interaction of the protein with IR, thereby regulating the tyrosine phosphorylation of 
IRS-1.26 It has been shown that in addition to regulating IR-IRS1 interactions, the PH 
domain of IRS-1 also regulates the ability of the protein to signal to downstream targets 
such as PI3K. Therefore, impairing the function of the PH domain (ie. in insulin 
resistance states) could both inhibit tyrosine phosphorylation of IRS-1 by the IR and alter 
efficient signal transduction to downstream targets. 27 
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2.1.2 IRS-1/PI3K/Akt Pathway  
     The PI3K-Akt pathway is a key regulator of cell proliferation, growth, survival and 
glucose metabolism. Extensive evidence suggests that this pathway is frequently 
deregulated in various cancer types, making its components molecular targets in cancer.28 
The family of lipid kinases, PI3Ks, is known to regulate essential cellular processes such 
as cell survival, proliferation and differentiation. PI3Ks are divided into three classes 
based on their structure and substrate specificity. The most commonly studied are the 
class I enzymes that are activated directly by cell surface receptors. In the insulin 
signalling pathway, PI3Ks are the major downstream substrates of IRS-1 and play pivotal 
roles in insulin-mediated glucose transport and translocation of the glucose transporter 
type 4 (GLUT4) from intracellular vesicles to the plasma membrane. Class IA PI3Ks 
which are a subset of Class I PI3Ks, are heterodimers comprised of a p110 catalytic 
subunit and a p85 regulatory subunit. 29 The p85 regulatory subunit binds to IRS-1 and 
the p110 catalytic subunit interacts with and  phosphorylates phosphatidylinositol in the 
cell membrane.  
     Upon interaction of IRS-1 with the p85 regulatory subunit of PI3K, the IRS-1/PI3K 
complex is recruited to the cell membrane where PI3K catalyzes the conversion of 
phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-triphosphate 
(PIP3). Then, PIP3 allows the recruitment and activation of other kinases such as 
phosphatidylinositol-dependent protein kinase 1 (PDK1) and Akt. Akt then becomes 
activated upon phosphorylation on Thr308 and Ser473 residues. (Figure 1) When Akt is 
active, it phosphorylates Akt Substrate of 160 kD (AS160) and facilitates the 
translocation of Glucose Transporter Type 4 (GLUT4), the protein responsible for 
insulin-stimulated glucose transport in skeletal muscle and adipose tissue, to the 
sarcolemma to allow glucose entry into the cell. 14,22,30  
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Akt, also known as protein kinase B, is a serine/threonine kinase which exists as three 
structurally similar isoforms: Akt1, Akt2 and Akt3 that are expressed in most tissues 29,31 
All three isoforms contain an N-terminal PH domain, a C-terminal regulatory domain and 
a central serine/threonine catalytic domain. Activation of Akt begins with its 
translocations to the plasma membrane facilitated by docking of PIP3 to the PH domain 
in the N-terminal region of Akt.29 This interaction results in a conformational change in 
Akt and exposes two important phosphorylation residues:Th308 and Ser473. In order to 
fully activate Akt, both amino acid residues must be phosphorylated. 29,31 
 
2.1.3 PI3K/Akt/mTOR Pathway 
    Once activated, Akt signalling can be propagated to many substrates including mTOR, 
a key regulator of protein translation. One of the well-studied substrates of Akt is the 
mammalian/mechanistic target of rapamycin complex 1 (mTORC1). Akt can activate 
mTORC1 by phosphorylating PRAS40 on T246 and TSC2 on multiple sites such as Ser 
939, Ser 1086 and T1422 and mitigating their inhibitory effect on mTORC129,32 Although 
mTORC1 is a downstream substrate of Akt, Akt itself can be activated by another mTOR 
complex, mTORC2 on S473 residues.31 The PI3K/Akt/mTOR pathway is constitutively 
activated in many cancer cell types and one of the involved mechanisms is the loss of 
tumor suppressor PTEN (phosphatase and tensin homolog). 28,29,31 As a lipid phosphatase, 
PTEN normally suppresses the activation of PI3K/Akt/mTOR pathway by removing a 
phosphate group from PIP3 and converting it to PIP2 , therefore, PTEN mutations or 
deletions are constantly observed in a variety of human cancers 33. Amplifications or 
mutations of PI3K and Akt are other mechanisms that lead to constitutive activation of 
this pathway.28,29,31  
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2.2 Insulin Resistance and T2DM 
     Type 2 diabetes mellitus (T2DM) is a growing health concern accounting for about 
90% of all cases of diabetes. In 2014, the WHO estimated the global prevalence of T2DM 
to be 9% among adults aged 18 years and older 2. T2DM is characterized by 
hyperglycemia as a result of either insufficient secretion of the hormone insulin, defects 
in insulin action or both. 4,34,35 Therefore, unlike in Type 1 diabetes mellitus (T1DM) 
where there is autoimmune destruction of β cells of the pancreas, in T2DM the body may 
produce insulin but it cannot effectively use it. T2DM is often preceded by a condition 
known as insulin resistance where peripheral target tissues such as liver, skeletal muscle 
and adipose tissue become unresponsive to the function of insulin, resulting in 
suppression of glucose uptake and metabolism. 3,4,35 Insulin is an essential hormone that 
regulates carbohydrate, fat and protein metabolism in the body and deregulation of its 
signalling is the hallmark of many complex metabolic and physiological disorders 
including obesity, cardiovascular disease and cancers. 5,6,16. Hence, it is crucial to 
understand the molecular mechanisms that regulate the development and pathogenesis of 
insulin resistance. In addition, since skeletal muscle is responsible for about 85% of 
postprandial glucose disposal and is the predominant site for insulin-stimulated glucose 
uptake, the study of insulin resistance in skeletal muscle is essential. 5,6 
 
2.3 Causes of Insulin Resistance 
2.3.1 Genetics 
     Genetic predisposition plays a major role in the development of insulin resistance and 
T2DM. Some of the early evidence came from classical experimental paradigms with 
twin, family and population studies. It was clearly demonstrated that the more closely two 
individuals were related, the more similar their glucose tolerance status. 35 Therefore, first 
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degree families of individuals with T2DM have a 3 times higher chance of developing the 
disease than individuals with no family history of the disease. Furthermore, the 
concordance rate of T2DM is significantly higher in monozygotic twins (70%) compared 
to dizygotic twins (20-30%).35–37 Individuals who have one parent with T2DM have a 
40% lifetime risk of developing the disease and those with both parents affected have a 
70% chance of developing the disease in during their lifetime 36.  
Thus, it is clear that T2DM has a strong genetic component with 30-70% of the risk 
attributed to genetics and a large variety of genes involved. 38,39  
     To date, multiple candidate genes for T2DM have been identified in various 
populations worldwide. However, it is still not clear exactly how many genes are 
involved and how they affect the development of the condition. Candidate genes were 
selected and studied because of their involvement in insulin action, glucose metabolism, 
β cell function and other metabolic conditions affecting T2DM. So far, some of the most 
promising candidate genes are Peroxisome Proliferator-Activated Receptor Gamma 
(PPARγ), Transcription Factor 7-Like 2 (T-Cell Specific, HMG-Box) (TCF7L2), 
Potassium Channel, Inwardly Rectifying Subfamily J, Member 11 (KCNJ11), and 
Calcium-Activated Neutral Proteinase 10 (CAPN10).  
What makes the PPARγ a strong candidate gene is that it encodes the nuclear receptor 
PPARγ, a molecular target for thiazolidinedione which is a class of insulin-sensitizing 
drugs used to treat T2DM. 36 TCF7L2 shows one of the strongest associations with 
T2DM. It is involved in the Wnt/ β-canenin signalling pathway which works to increase 
insulin sensitivity and pancreatic islet development. High risk TCF7L2 genotype reduces 
insulin secretion, thereby, confirming the importance of TCF7L2 variants in β cell 
function. 38,39 KCNJ11 is part of the ATP-sensitive potassium channel with a major role 
in regulating the release of hormones insulin and glucagon, therefore, mutations in this 
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gene can affect insulin secretion.35–38 CAPN10 gene encodes ubiquitous, calcium-
dependent cysteine proteases. Calpain-10 is a protein encoded by the CAPN10 gene. It is 
an important protein in β cell function and emerging evidence suggests that it plays a role 
in facilitating GLUT4 translocation, therefore, variations in calpain-10 activity can 
modulate insulin secretion and enhance susceptibility to T2DM. 36–39 
     Maturity-onset diabetes of the young (MODY) is an uncommon type of diabetes that 
usually occurs before the age of 25 in less than 5% of all cases of T2DM. The 
pathophysiology of MODY involves mutations in transcription factor genes that are 
critical in β cell function. Molecular genetics studies have shown that there are at least six 
forms of MODY caused by various gene mutations. MODY1 is caused by mutations in 
hepatocyte nuclear factor-4α (HNF4A) while MODY2 results from glucokinase (GCK) 
gene mutations. Mutations in the hepatocyte nuclear factor-1α (HNF1A) gene result in 
MODY3 which is the most frequent cause of the disease. Finally, MODY5 and 6 are 
caused by mutations of the hepatocyte nuclear factor-1β (HNF1B) and neurogenic 
differentiation 1(NEUROD1) genes respectively.  
Even though genetic factors are a significant component of T2DM development, it is 
clear that environmental factors also play a major role in the progression of the disease. 
Two key environmental risk factors contributing to T2DM are obesity and a sedentary 
lifestyle (physical inactivity).      
 
2.3.2 Lack of Physical Activity and Obesity 
     The increasing cases of T2DM in recent years can be primarily explained by the 
dramatic growth in obesity rates worldwide. It has been estimated that up to about 80% of 
all new T2DM cases are attributed to obesity 40. Body fat distribution is another important 
factor in T2DM risk. The waist-to-hip ratio (WHR) which is a measure of abdominal 
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obesity, has a stronger association with T2DM than the standard measure of obesity, 
BMI.41 Physical inactivity is another major risk factor for T2DM. Regular physical 
activity not only maintains a healthy weight, but also improves glucose and fat 
metabolism which reduce T2DM risk.  
     There are two well-defined mechanisms of glucose uptake by muscle: one is insulin-
dependent which occurs at rest and post and postprandially and the other through 
exercise. 42 Epidemiological studies strongly support the effect of exercise in preventing 
obesity and T2DM. Moderate exercise such as brisk walking or cycling for  more than 30 
minutes per day has been shown to significantly lower the risk of T2DM 42–44. Studies 
have shown that even low intensity aerobic exercise is beneficial in enhancing skeletal 
muscle insulin-stimulated glucose disposal and GLUT4 protein content.43,45 Other studies 
have found that the effect of aerobic exercise on improving insulin signalling is dose and 
intensity-dependent. 41 A combination of aerobic and resistance training may be more 
effective in regulating glucose uptake than any of them alone. This is because resistance 
training results in increased muscle mass and can contribute to glucose uptake without 
modifying the muscle’s intrinsic ability to respond to insulin, whereas aerobic exercise 
enhances insulin’s action without altering muscle mass. 42  
     The key mechanisms responsible for the beneficial effects of physical activity on 
insulin sensitivity include enhancement of glucose transport mediated by increased 
expression of GLUT4 proteins and translocation of GLUT4 from intracellular vesicles to 
sarcolemma. 45–48 Other benefits of physical activity on insulin sensitivity include 
promotion of muscle vascularization and mitochondrial biogenesis. 41 Kennedy et. al. 49 
demonstrated that even a single bout of moderate intensity exercise is effective in 
promoting the translocation of GLUT4 to the plasma membrane in skeletal muscle of 
T2DM patients. Other studies have also found that contraction-mediated glucose 
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transport via increased GLUT4 translocation, involves AMPK activation and is insulin-
independent. 42,47,50 Despite the importance of physical activity in the prevention and 
treatment of insulin resistance and T2DM, nutrition has a more profound impact on 
regulation of insulin resistance since insulin is only secreted in response to nutrient 
availability.  
  
2.3.3 Nutrition 
    Food is an important regulator of insulin sensitivity and nutrient overload can trigger 
the progression of metabolic disorders such as T2DM and cardiovascular disease 4,15,51. 
Two key nutrients that have been the focus of research in studies of skeletal muscle 
glucose metabolism are lipid and protein. 
 
2.3.3.1 High Lipid Intake 
     High fat diets combined with a sedentary lifestyle are major contributing factors for 
the high prevalence of obesity and T2DM in Western lifestyle. Epidemiological evidence 
supports the effect of high fat diets in the development of obesity and other physiological 
complications. Such studies indicate a direct relationship between the amount of dietary 
fat consumed and the level of obesity. Overconsumption and weight gain associated with 
high fat diets have consistently been shown to be caused by the high caloric density and 
low satiety properties of such diets.52  
     The role of dietary fat in the development of T2DM has received clinical interest for 
many years. Many previous studies have established that fat-enriched diets significantly 
alter the composition of cell membrane phospholipids. 53 These cell membrane alterations 
have been shown to affect insulin binding and action, GLUT4 translocation and other 
cellular functions which are all membrane-mediated events. 53,54 Because of their close 
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contact with the lipid bilayer, membrane-associated events such as the coupling between 
transporters and receptors, are influenced by dietary fat. Several studies have examined 
the effect of increasing plasma fatty acid levels by infusion of lipid in humans and 
rodents and found an inhibitory effect on insulin-mediated activation of the IRS-
1/PI3K/Akt pathway in skeletal muscle.55,56 Other studies have found similar effects of 
high plasma free fatty acid levels on impairment of the IRS-1/PI3K/Akt activity and have 
attributed these effects mainly to defects in IRS-1 tyrosine phosphorylation and 
ultimately inhibition of insulin-induced glucose transport. 57 
     Therefore, rises in plasma free fatty acid concentrations result in the development of 
insulin resistance through inhibition of insulin-stimulated glucose transport. However, it 
is important to note that different types of fatty acids exert different effects on insulin 
signalling.  For instance, Harding et al. found diets with a higher polyunsaturated 
saturated fat (PUFA) to saturated fat ratio, reduced the risk of T2DM independent of age, 
sex, family history of T2DM, physical activity, protein intake and smoking status 58. The 
beneficial effects of n-3 PUFA have been shown to include reduction of serum lipids and 
lipoproteins, lowering blood pressure and impairment of platelet aggregation which are 
factors that help reduce the risk of T2DM. In animal studies, diets enriched with PUFA 
enhanced peripheral glucose utilization 59. Conversely, saturated fat and animal fat intake 
has been shown to be strongly associated with increased risk of T2DM. 53,58 This is 
because a greater saturated fatty acid content of membrane phospholipids has been 
reported to increase insulin resistance 53,54,60.  
     Trans fatty acids (TFAs) which are created through the transformation of PUFAs from 
their natural cis form to the trans form are abundant in processed foods in Western diets 
and have been shown to have implications in insulin resistance and T2DM 61. Salmerón et 
al. examined the effect of TFAs on the risk of T2DM in a large sample of women and 
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found a positive association 62. Their results were consistent with previous human and 
animal studies indicating adverse metabolic effects associated with TFAs intake on 
lipoprotein metabolism and insulin sensitivity. 61,63 It has been suggested that TFAs may 
reduce insulin sensitivity by promoting systemic inflammation as reflected by increased 
levels of inflammatory markers TNFα, IL-6, and C-reactive protein 61.   
 
2.3.3.2 High Protein Intake  
      High protein diets have frequently been used in the management of obesity. The 
Recommended Daily Allowance for protein is 0.8 g/kg of body weight, however, some 
studies suggest that consuming higher amounts of proteins produce positive metabolic 
effects. High protein diets have been shown to increase thermogenesis, energy 
expenditure, satiety and assist weight loss. 10 In particular, BCAAs have received more 
attention because of their anabolic effects on muscle and their anti-obesity effects. 
Studies suggest that diets high in BCAAs often have positive effects in weight 
management, glucose homeostasis and protein synthesis 6,64–66 . In addition, amino acids, 
particularly leucine, stimulate protein synthesis by promoting mTORC1 activity, leading 
to skeletal muscle anabolism and growth 12,14,67–69. The anabolic effect of amino acid 
intake on muscle is due to increased muscle protein synthesis 30,48,64,67,70. The major 
signalling factors involved in synthesis of proteins in skeletal muscle are mTORC1 and 
its two downstream substrates, ribosomal protein S6 kinase 1 (S6K1) and eukaryotic 
translation initiation factor 4E-binding protein 1 (4EBP-1) 12,70,71. Of all three BCAAs, 
leucine has been shown to be the most potent nutrient signal in activating 
mTORC113,14,68.  
     Consumption of dietary protein increases the secretion of insulin into the bloodstream 
which enhances the clearance of glucose from the blood. However, in the long term, high 
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intake of dietary protein is associated with a higher risk of T2DM in healthy individuals. 
72In obese individuals however, consumption of high protein diets might be helpful for 
improving insulin sensitivity in the presence of weight loss which has a significant 
beneficial effect on enhancing insulin sensitivity. Furthermore, in studies where obese or 
T2DM subjects consumed high protein diets without weight loss, the results are 
inconclusive, indicating the importance of weight loss in improving insulin sensitivity 
and glucose metabolism.72 
     In a study done by Linn et al. plasma insulin concentrations were found to be elevated 
not only by a single protein-rich meal but also by long term high protein intake in healthy 
non-obese individuals. 73 They found prolonged protein intake (for 6 months) was 
associated with increased fasting glucose production, increased gluconeogenesis and 
reduced insulin sensitivity. Other observational studies have also shown associations 
between long-term high protein intake and the risk for developing T2DM and metabolic 
syndrome 74.   
     Despite the beneficial anti-obesity effects associated with BCAA consumption, 
emerging evidence suggests elevated levels of circulating BCAAs may also be implicated 
in the development of insulin resistance and T2DM 5,6. Normal BCAA metabolism 
appears to be altered in insulin resistance, leading to high blood concentrations of 
BCAAs. One of the proposed mechanisms relating high levels of BCAAs to insulin 
resistance is the persistent activation of mTORC1/S6K1 pathway as a result of excess 
leucine levels, which subsequently causes an impairment of insulin signalling 6,75. 
 Hyper-phosphorylation of S6K1T389 due to amino acid overload results in a negative 
feedback loop leading to phosphorylation of IRS-1 on serine residues (Ser 612,307, 1101) 
rather than the normal tyrosine residues (Tyr 608, 628). 23,71 Serine phosphorylation of IRS-1 
impairs its function and inhibits further signalling to P13K/AKT pathway. 23, (Figure 2) As a 
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result, GLUT4 cannot be recruited to the plasma membrane, leading to impairment of 
glucose transport and the development of insulin resistance and T2DM. 14,71 The 
importance of persistent activation of the mTORC1/S6K1 pathway has been shown in 
animal studies with disruptions in S6K1 activity. For instance, Um et al. reported that 
S6K1-deficient mice are protected against obesity and insulin resistance, thereby, 
signifying the importance of S6K1 in negative regulation of insulin signalling. 76 
 
2.4 Molecular Mechanisms of Insulin Resistance 
2.4.1 Accumulation of Lipid Intermediates  
     Studies have consistently demonstrated that lipid-induced insulin resistance may 
result from accumulation of intracellular lipid metabolites which have deleterious effects 
on insulin-mediated IRS-1 tyrosine phosphorylation. 56 Specifically, intracellular lipid 
intermediates diacylglycerols (DAGs) and ceramides have been shown to be implicated 
in the pathogenesis of insulin resistance and T2DM. Ceramides are mainly membrane 
lipids and are the precursors for the formation of sphingomyelin, one of the primary lipids 
in the lipid bilayer. In rodent models, rises in hepatic and muscle ceramide content has 
been found to be associated with insulin resistance and can be toxic in certain cell types 
such as the pancreatic β cells and cardiomyocytes 77. The role of ceramides in insulin 
resistance came from observations that they inhibit insulin-stimulated glucose transport 
and they do so by inhibiting insulin-mediated activation of Akt 78.   
     The lipid second messenger DAG is produced upon activation of the phosphoinositide 
signalling pathway which plays important roles in cell signalling, lipid signalling and 
membrane trafficking 79. DAG is produced from PIP2 and is a physiological activator of 
protein kinase C (PKC) in addition to interacting with other signalling molecules such as 
small G proteins. Persistent activation of PKC has been shown to correlate with increased 
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serine phosphorylation of the insulin receptors, an effect that mediates insulin 
resistance.80,81 The effect of DAG on insulin resistance can be explained by genetic 
manipulations of the enzyme that acylates DAGs into triglycerides. Liu et al. examined 
the effect of overexpression of diacylglycerol acyltransferase (DGAT) in skeletal muscle 
of mice and found that these mice exhibit increased levels of triglycerides, reduced levels 
of ceramides and DAGs and improved muscle and whole-body insulin sensitivity 80. This 
finding recapitulates “the athlete’s paradox” phenomenon which refers to endurance 
athletes being very insulin-sensitive despite having high triglyceride contents 77. Liu el al. 
also found DGAT overexpression to attenuate DAG-mediated PKC activation and 
downstream c-Jun N-terminal kinase 1(JNK1) response. JNK1 is a a stress mediator 
protein kinase activated by various environmental stresses, inflammatory cytokines and 
growth factors. JNK1 phosphorylates IRS-1 on Ser307 residues and suppresses the 
insulin-induced IRS-1/PI3K pathway activation.80  
     Thus, accumulation of intracellular lipid intermediates such as DAG and ceramide in 
skeletal muscle and liver may be a common mechanism leading to impairment of insulin 
of signalling and insulin resistance.  
 
2.4.2 Chronic Inflammation 
    Chronic and low grade inflammation is associated with the pathogenesis of chronic 
diseases such as T2DM, atherosclerosis and cancer. Inflammation is a physiological 
process characterized by increased circulating levels of proinflammatory cytokines or 
elevated count of white blood cells. In general, inflammation is a protective mechanism 
required for initiating tissue repairing, healing wounds and battling infections in the body. 
However, overactivation of the inflammatory response has deleterious effects. In states of 
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obesity and T2DM, proinflammatory cytokines enter the bloodstream from adipose tissue 
and liver and cause systemic inflammation.  
     Early studies in T2DM patients observed lowering of blood glucose levels in response 
to the anti-inflammatory drug aspirin 82. In rodent models, an increase in the 
proinflammatory cytokine TNF-α, was also observed in the adipose tissue of 
obese/insulin-resistant mice, indicating an association with insulin resistance 83. More 
recent animal and human studies found elevated levels of inflammatory markers such as 
C reactive protein (CRP), plasminogen activator inhibitor-1 (PAI-1), interleukin 6 (IL-6) 
and other inflammation mediators in the plasma of obese patients and animals 83,84. TNF-
α has been shown to inhibit normal IRS-1 signalling 83. Other signalling molecules such 
as JNK1 (c-Jun N-terminal kinase) and IκB kinase β (IKKβ) have also been found to be 
elevated in the adipose tissue and liver of obese patients and their activation appears to 
involve TNF-α-mediated IRS-1 inhibition. 84  
     NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) is a protein 
complex involved in survival and cytokine production, therefore, it regulates many genes 
involved in inflammation. IKKβ is a central regulator of inflammatory responses and is 
the primary kinase mediating NF-κB activation.85 The IKKβ/NF-κB pathway is a key 
inflammation signaling pathway and is extensively studied in cancer and obesity. IKKβ 
inhibits insulin signaling by phosphorylating IRS-1 at multiple serine residues including 
Ser307 in adipocytes.84 The inhibitory effects of IKKβ on insulin signalling is supported 
by evidence from animal studies. Arkan et al. found that IKKβ knockout mice 
demonstrated improved insulin sensitivity and greater protection from high fat diet-
induced insulin resistance in both the liver and muscle. 86  
     Peroxisome proliferator-activated receptor gamma (PPARγ) is a nuclear receptor 
responsible for lipid synthesis and storage as well as regulation of cellular differentiation, 
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proliferation and metabolism.56,84 It regulates a number of genes involved in insulin 
signalling, including the ones that control the expression of TNF-α and other 
proinflammatory cytokines.87 Reduction of PPARγ has been shown to contribute to 
insulin resistance. It has been suggested that TNF-α inhibits the function of PPARγ which 
induces insulin resistance 84,87. Importantly, PPARγ agonists such as thiazolidinediones, 
can antagonize the synthesis of TNF-α or its action in adipocytes. 88 
 
2.4.3 Oxidative Stress 
     Oxidative stress results from the imbalance between the production of reactive 
oxygen species (ROS) in the body and their disposal. ROS is mainly produced in the 
mitochondria when fatty acids or glucose are oxidized to generate ATP or heat. 84 Even 
though ROS production is necessary for normal signal transduction in cells, its 
overproduction will cause oxidative stress. In conditions of obesity, excess levels of fatty 
acids and glucose in the mitochondria produce oxidative stress, since obesity is normally 
associated with hyperglycemia and hyperlipidemia. 84 ROS can also be induced by other 
factors such as hypoxia.  
     Oxidative stress has been reported to be closely associated with insulin resistance and 
T2DM. Under diabetic conditions, glucose toxicity occurs as a result of chronic 
hyperglycemia which impairs insulin biosynthesis and secretion.89 Production of ROS as 
a consequence of hyperglycemia has been shown to decrease insulin gene expression and 
secretion and ultimately β-cell dysfunction. Lipotoxicity is also involved in inhibition of 
β-cell function found in T2DM. Exposure of islets to free fatty acids has been shown to 
induce ROS and reduce insulin secretion and β-cell dysfunction.89 
     Furthermore, activation of the JNK pathway is also involved in pancreatic β-cell 
dysfunction observed in T2DM. This pathway is induced by many factors including 
  19 
increased levels of free fatty acids, inflammatory cytokines, endoplasmic reticulum (ER) 
stress and ROS which are all involved in the development of T2DM. 89The JNK pathway 
has been reported to be involved in ROS-mediated reduction of insulin gene expression 
and its suppression can protect β-cell from ROS damage. 90 Previous studies also suggest 
that ROS can inhibit the IRS-1/PI3K pathway and thereby, disrupt insulin-mediated 
GLUT4 translocation in 3T3-L1 adipocytes. 91 The importance of ROS implication in 
T2DM is highlighted by animal studies in which ROS suppression in obese/ type-2 
diabetic mice was shown to rescue β-cell function and insulin sensitivity and lead to 
improved glucose tolerance.92  
 
2.4.4 mTORC1/S6K1 Pathway  
     Chronic activation of the mTORC1/S6K1 pathway is one of the mechanisms involved 
in the development of T2DM and other pathophysiological conditions such as obesity and 
cancer. Persistent activation of mTORC1 as a result of nutrient overload, results in 
phosphorylation and activation of S6K1 and subsequent serine phosphorylation of IRS-1 
which disrupts its normal activity and degrades the protein. This negative feedback loop 
has been shown to have profound implications in insulin resistance and T2DM. In-vivo 
studies further support the implication of S6K1/IRS-1 negative feedback loop in the 
pathogenesis of insulin resistance and T2DM, whereby S6K1-deficient mice show 
improved insulin sensitivity despite being on a chronic high fat diet.76 Therefore, the 
mTORC1/S6K1 pathway has major implications in the development of insulin resistance 
and T2DM.  
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2.5 Mammalian Target of Rapamycin (mTOR) 
    The mammalian/mechanistic target of rapamycin (mTOR), a 289-kD protein, is a 
serine/threonine protein kinase belonging to the family of PI3K-related kinases. 93 The 
mTOR signalling pathway integrates intracellular and extracellular signals and is a 
central regulator of cell growth, metabolism, proliferation, survival, protein synthesis and 
ribosome biogenesis. mTOR interacts with several other proteins to form two distinct 
complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) with 
different subunit compositions, cellular functions and type of regulation. 93–96 One 
distinguishing feature of the two complexes is that although the immunosuppressant drug, 
rapamycin, perturbs mTORC1 signalling, short-term treatment with rapamycin does not 
inhibit mTORC2 signalling. 94 Since mTOR is generally deregulated in states of obesity, 
T2DM and cancer, it is important to understand the processes involved in the mTOR 
signaling network. 
 
2.5.1 Mammalian Target of Rapamycin Complex 1 (mTORC1) 
     mTORC1 is comprised of five proteins: mTOR, the catalytic subunit of the complex, 
regulatory-associated protein of mTOR (Raptor), mammalian lethal with Sec13 
protein 8 (mLST8, also known as GbL), DEP-domain-containing mTOR-interacting 
protein (Deptor) and proline-rich AKT substrate 40 kDa (PRAS40). 14,94,97 It has been 
suggested that Raptor affects mTORC1 activity by regulating the complex assembly and 
recruiting mTOR substrates. Even though mLST8 is a positive regulators of mTORC1, its 
function in mTORC1 activity is still unclear as in-vivo deletion of this protein does not 
affect mTORC1 function 93,97. PRAS40 and Deptor are characterized as a negative 
regulator of mTORC1. When mTORC1 activity is reduced, PRAS40 and Deptor are 
recruited to the complex where they inhibit mTORC1. PRAS40 has been suggested to 
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regulate mTORC1 activity by directly inhibiting substrate biding. When mTORC1 
becomes activated, it directly phosphorylates PRAS40 and Deptor, thereby reducing their 
physical interaction with mTORC1.93,95  
 
2.5.2 Mammalian Target of Rapamycin Complex 2 (mTORC2) 
     Some of the proteins are common to mTORC1 and mTORC2. In addition to mTOR, 
mLST8 and Deptor, mTORC2 has three other components: rapamycin-insensitive 
companion of mTOR (Rictor), mammalian stress-activated protein kinase interacting 
protein (mSIN1) and protein observed with Rictor-1 (Protor-1). 93,94 Although mTORC2 
is not as well characterized as mTORC1, its components have been identified and 
studied. Rictor and mSIN1 have been shown to interact with and stabilize each other, 
forming the structural foundation of mTORC2. 98,99 Rictor also interacts with Proctor-1 
but the exact physiological function of this interaction is not yet clear. Similar to its effect 
in mTORC1, Deptor is a negative regulator of mTORC2 activity and it is the only 
endogenous inhibitor of mTORC2 so far. In contrast to what is observed with mTORC1, 
mLST8 is essential for mTORC2 function. This is supported by studies in which mLST8 
knockout significantly reduced the stability and activity of mTORC2. 97 
 
2.5.3 mTORC1 and Downstream Substrates 
     The focus of my thesis will be on mTORC1 since it is the prominent regulator of cell 
growth and metabolism and integrates anabolic signals from amino acids and growth 
factors. Protein synthesis, an anabolic process required for cell growth is by far the most 
well-known process controlled by mTORC1. mTORC1 positively regulates protein 
synthesis by phosphorylating its two downstream substrates: the eukaryotic translation 
initiation factor (eIF) 4E-binding protein 1 (4E-BP1) and p70 ribosomal S6 kinase 1 
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(S6K1). Phosphorylation of these proteins allows mRNA biogenesis and translation and 
promotes protein synthesis. 96,100  
 
2.5.3.1 Ribosomal Protein S6 Kinase-1 (S6K1) 
     S6K1 particularly regulates protein synthesis, ribosome biogenesis and insulin-
mediated anabolic responses. S6K1 belongs to the serine/threonine protein kinases 
family. Phosphorylation of S6K1 by mTORC1 occurs on the T389 residues. Activation of 
S6K1 by mTORC1 stimulates mRNA biogenesis, cap-dependent translation and 
elongation, and translation of ribosomal proteins through regulation of proteins such as 
the tumor suppressor programmed cell death 4 (PDCD4), ribosomal protein S6 and 
eukaryotic elongation factor 2 kinase (eEF2K). As a result, S6K1 promotes protein 
synthesis by enhancing the translational capacity of the cell. 100 
 
2.5.3.2 Eukaryotic translation initiation factor 4E-binding protein 1 (4E-
BP1) 
     4E-BP1 is involved in protein translation. Regulation of protein translation is 
controlled with ribosome recruitment at the 5’ end of an mRNA at the position of a start 
codon. A number of translation initiation factors facilitate ribosome binding to the 5’ end 
of an mRNA. There is a cap structure specific to the 5’ end of all nuclear-transcribed 
mRNAs which is specifically recognized by eukaryotic translation initiation factor 4E 
(eIF4E). eIF4E is one of the protein components of the trimeric complex known as eIF4F. 
The other two proteins are eIF4A, which is an RNA helicase and eukaryotic translation 
initiation factor 4G (eIF4G) and is a scaffolding molecule. eIF4E provides the essential 
interface between mRNA and the recruitment of eIF4A and eIF4G necessary for 
translation initiation. 4E-BP1 belongs to a family of translation repressor proteins and it 
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negatively regulates mRNA translation through its effect on eIF4E and eIF4G. 4E-BP1 
competes with eIF4G to bind to dorsal surface of eIF4E. When 4E-BP1 is in a 
hypophosphorylated state, it prevents the formation of the eIF4F complex by preventing 
the recruitment of eIF4G to the 5’ cap of mRNA. However, upon phosphorylation by 
mTORC1, a conformational alteration releases eIF4E, allowing it to recruit eIF4G to the 
5’ cap of mRNAs to allow cap-dependent translation. Thus, phosphorylation of 4E-BP1 
by mTORC1 inhibits the suppression of mRNA translation. 
 
2.6 Upstream Regulators of mTORC1  
2.6.1 Growth Factors  
         As mentioned earlier, mTORC1 is the better characterized form of the two mTOR 
complexes and it senses and integrates inputs from intracellular and extracellular cues 
such as growth factors, energy status, stress, oxygen and amino acids. 94 Activation of 
mTORC1 by insulin or insulin-like growth factor 1 (IGF-1) occurs via Akt. Activated 
Akt stimulates mTORC1 signalling by phosphorylating and inhibiting the tuberous 
sclerosis complex (TSC1/2).93,101 TSC1/2 inhibits the activity of mTORC1 by functioning 
as a GTPase-activating protein (GAP) towards the Ras homolog enriched in brain (Rheb) 
GTPase, which acts as an activator of mTORC1. 93,102,103 When Rheb is in its GTP-bound 
form, it directly interacts with mTORC1 resulting in strong stimulation of the kinase. 
Hence, TSC1/2 negatively regulates mTORC1 by converting Rheb into its inactive GDP-
bound form. 93 Akt also regulates mTORC1 in a TSC1/2-independent manner by 
phosphorylating PRAS40 (an inhibitor of mTORC11) and dissociating it from raptor.  
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2.6.2 Stress 
     In addition to growth factors, many stress signals also act on mTORC1 through the 
TSC1/2 complex. The best characterized stress signals to date are DNA damage, low 
oxygen and low energy levels. The mTORC1 pathway directly senses low ATP levels 
through a mechanism involving AMPK. In response to hypoxia or low energy status, 
AMPK phosphorylates TSC1/2 and stimulates its GAP activity towards Rheb. 
Furthermore, AMPK phosphorylates raptor, leading to inhibition of mTORC1 through 
allosteric mechanisms. 94,96 Hypoxia also leads to low energy levels as a result of 
impaired mitochondrial respiration. Hypoxia stimulates the expression of regulated in 
development and DNA damage responses 1 (REDD1) gene, which suppresses mTORC1 
through a TSC1/2-dependent mechanism.95 It has been shown that in response to 
hypoxia, REDD1 inhibits the TSC2/14–3–3 interaction and mTORC1 activity 104. DNA 
damage can also negatively regulate mTORC1 activity through multiple mechanisms that 
involve p53-dependent upregulation of AMPK. 94 
 
2.6.3 Amino Acids 
     In addition to being the building blocks of proteins, amino acids, particularly leucine, 
are able to stimulate mTORC1 activity leading to increased muscle protein synthesis and 
decreased proteolysis. 30,64,70,105 The importance of amino acids in organismal growth and 
homeostasis was appreciated decades ago when early studies showed that rats deprived of 
leucine displayed significant weight loss, muscle waste and eventually death 106. It was 
also observed that amino acid deprivation results in rat liver autophagy (the process of 
cellular self-eating via lysosomal degradation).107 Leucine and arginine have been shown 
to be the most potent stimulators of mTORC1 activity among all the amino acids 94. In 
mammalian and yeast cell lines, withdrawal of amino acids from the culture media 
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significantly suppresses mTORC1 activity 108. When there are sufficient levels of amino 
acids in the cell, mTORC1 becomes active due to its lysosomal localization 109. Amino 
acid-dependent activation of mTORC1and its localization to the lysosome require the 
Rag GTPases.13,94,109,110 Rag proteins are the central regulators of amino acid signalling to 
mTORC1 because they regulate the subcellular localization of mTORC1 and its activity. 
In mammals there are four Rag proteins and they exist as heterodimers where RagA and 
RagB bind to either RagC or RagD 110. Amino acids control the nucleotide loading of the 
Rag proteins causing them to switch to an active conformation, which then bind and 
activate mTORC1. When the Rag proteins are in the RagA/B GTP, Rag C/D GDP form, they 
display maximum activity and binding to mTORC1 110. When active, the Rag GTPases 
recruit mTORC1 to the lysosomal surface where it directly interacts with Rheb to become 
activated. 93 On the lysosomal surface, the Rag GTPases dock on a complex called 
Ragulator. This complex is essential for amino acid-mediated activation of mTORC1 
similar to Rag GTPases because it recruits mTORC1 to the lysosome in response to 
amino acids. The localization of the Ragulator and the Rag GTPases on the lysosomal 
surface suggests an important role for this organelle in amino acid sensing by the 
mTORC1 pathway. Recently, a model of amino acid sensing has been proposed in which 
amino acids accumulate in the lysosomal lumen and initiate signaling through a 
mechanism requiring the vacuolar H+-adenoside triphosphate ATPase (v-ATPase). 13 
When v-ATPase subunits are depleted, amino acid-induced translocation of mTORC1 to 
the lysosomal surface and downstream signaling is blocked. The v-ATPase directly 
interacts with the Ragulator and provides a link between Rag GTPase and the v-ATPase 
on the lysosomal surface. Moreover, the mTORC1 pathway regulates the expression of v-
ATPase, suggesting that a feedback loop exists between mTORC1and lysosome 
function.13,111  
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     Another protein implicated in amino acid sensing by mTORC1 is the class 3 PI3K or 
the mammalian vacuolar protein sorting 34 homologue (hVPS34). Amino acids cause an 
increase in intracellular calcium levels which stimulate mTORC1 and hVps34 activation. 
This rise in intracellular calcium levels promotes the binding of calmodulin to hVps34.112 
     Interestingly, a recent study by Demetriades et al. found the TSC1/2 complex is also 
involved in the amino acid-mediated regulation of mTORC1, thereby placing this 
complex at the intersection of all signalling inputs to mTORC1109. They proposed a 
model in which TSC1/2 complex is part of the molecular machinery required for 
mTORC1 to respond to amino acid starvation. They found that TSC1/2 complex responds 
to amino acid starvation by changing its subcellular localization. They also showed that 
upon amino acid withdrawal, TSC2 is required for mTORC1 to be fully released from the 
lysosome. 109 
     Therefore, elevated levels of amino acids can result in hyperactivation of the 
mTORC1 pathway which can create an abnormal metabolic response and lead to the 
development of insulin resistance.   
 
2.7 Branched-chain Amino Acids (BCAAs) and Metabolic Health 
     BCAAs refer to the three essential amino acids: leucine, isoleucine and valine. These 
amino acids cannot be synthesized in the body, thus, they must be obtained through diet. 
BCAAs comprise a large part of dietary amino acids. The percentage of BCAAs in food 
sources varies between 20 and 25% of total protein content. 19 There is abundant evidence 
for the critical role of BCAAs in regulating the maintenance and growth of skeletal 
muscle by enhancing protein synthesis 64,67,113and inhibiting protein breakdown114. 
BCAAs also play important roles in attenuating exercise-induced muscle damage and 
delayed-onset muscle soreness114,115, lowering the loss of lean body mass during weight 
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loss116 and preserving and restoring muscle mass in patients with liver disease such as  
advanced cirrhosis 19. BCAAs and insulin are anabolic signals that affect the growth of 
energy-consuming tissues, mediated in part through their ability to activate the mTORC1 
pathway. Even though BCAAs are believed to improve many aspects of health, several 
lines of evidence suggest their implication in the development of insulin resistance and 
T2DM. Therefore, the idea that dietary BCAAs or their supplementation might be 
beneficial in preventing metabolic disorders is controversial.  
 
2.7.1 BCAA Metabolic Pathway 
     The metabolism of BCAAs involves two common steps. The first step occurs in most 
peripheral tissues except the liver. This step involves the reversible transamination of 
BCAAs and is catalyzed by the mitochondrial isoform of the enzyme branched-chain 
amino acid transferase (BCATm) encoded by the BCAT2 gene. In the transamination step 
catalyzed by BCATm, an α-amino group of BCAAs is transferred to α-ketoglutarate to 
form the three branched-chain ketoacids: α-ketoisocaproic acid (KIC), α-ketoisovaleric 
acid (KIV), and α-keto-β-methylvaleric acid (KMV). While BCATm is expressed in most 
non-neuronal tissues except the liver, the cytosolic isoform of the enzyme (BCATc) is 
expressed in the central nervous system and peripheral nerves.66  
The second step in BCAA catabolic pathway is the irreversible oxidative decarboxylation 
of the ketoacids catalyzed by the mitochondrial branched-chain α-ketoacid 
dehydrogenase complex (BCKDH) which yields the three CoA derivatives of BCAAs: 
propionyl-CoA, acetoacetate and acetyl-CoA.117,118 The metabolic pathway further 
continues and produces intermediates used in the TCA cycle. The BCKDH complex 
contains three enzymes: E1(branched-chain α-ketoacid decarboxylase), E2 (dihydrolipoyl 
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transacylase) and E3 (dihydrolipoyl dehydrogenase). Phosphorylation and 
dephosphorylation of the E1 α subunit regulates the activity of BCKDH complex. 5 
The first product of leucine catabolism, α-ketoisocaproicacid (KIC) has been the focus of 
research as there is some evidence for its involvement in mTORC1 activation and protein 
synthesis. Studies in primary adipocytes have shown KIC to be as effective as leucine in 
stimulating mTORC1signalling 70. However, this could be due to the conversion of KIC 
back to leucine, since the first reaction in leucine catabolism is reversible and therefore, 
increased leucine levels may account for increased stimulation of mTORC1 signalling in 
response to KIC treatment. 119 In fact, She et al. examined mTORC1 signalling in BCAT2 
knockout and wild-type mice to investigate the role of leucine metabolism in mTORC1 
signalling pathway 66. They observed increased phosphorylation of S6K1 and 4E-BP1 
only in the skeletal muscle of wild-type mice suggesting that conversion of leucine to 
KIC may not be essential for stimulating mTORC1 activity by leucine. Other studies 
have also reported that leucine is a direct-acting nutrient signal and its metabolism may 
not be required for mTORC1 activation in adipose tissue.18 Because current data is 
inconclusive, further research is needed to understand whether KIC can promote 
mTORC1 activation independently of leucine or if conversion of KIC back to leucine is 
required to promote mTORC1 activity. 
     Another metabolite of leucine β-hydroxy-β-methylbutyrate (HMB) has also been 
studied in the context of muscle protein turnover. HMB has been shown to stimulate 
protein synthesis and increase skeletal muscle hypertrophy via the mTORC1 pathway in 
rats 120. Furthermore, an in-vitro study by Girón et al., found that conversion of leucine to 
HMB is required for potent stimulation of mTORC1 and enhancing protein synthesis in 
L6 myotubes and that HMB is more effective than leucine in stimulating protein 
synthesis in skeletal muscle.121 HMB has also been reported to have anti-catabolic 
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effects, attenuate muscle proteolysis during exercise and increase muscle strength and 
performance.120,122 Even though a combination of HMB, resveratrol and metformin has 
been recently shown to improve insulin sensitivity in C2C12 muscle cells, the 
independent effect of HMB on insulin signalling has not yet been studied.123 Since, this 
particular metabolite of leucine is able to stimulate mTORC1 activity, it would be 
interesting to determine if and how it is implicated in the development of insulin 
resistance.    
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Fig 3. BCAA metabolic pathway. The three branched-chain amino acids, leucine, 
isoleucine, and valine are deaminated via the action of the branched-chain 
aminotransferase (BCAT2) enzyme. This step is reversible. The subsequent α-ketoacids 
then undergo oxidative decarboxylation via the action of the enzyme complex, branched-
chain ketoacid dehydrogenase (BCKD). This reaction yields the CoA derivatives of the 
decarboxylated ketoacids. The third step in BCAA catabolism is a dehydrogenation step 
that involve three individual enzymes, one for each of the CoA derivatives generated via 
the BCKD reaction. The remainder of the catabolic pathways for the three BCAAs 
diverges and generates substrates for the Krebs cycle.  
Figure adapted from “Branched-chain amino acids in metabolic signalling and insulin 
resistance”, by C.J. Lynch and S.H. Adams, 2014, Nature Reviews Endocrinology, 10, 
723–736. 
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2.7.2 The link between BCAAs, mTORC1 and Insulin Resistance- 
BCAA Paradox 
     As mentioned earlier, BCAAs have positive anabolic effects, however, paradoxically, 
they have been shown to be associated with obesity, insulin resistance and T2DM.6 A lot 
of the evidence comes from metabolomics studies. Metabolomics is the comprehensive 
measurement of processes involving the identification and quantification of cellular 
metabolites and is a widely used technique to study metabolic diseases. Metabolic 
profiling has provided new insight into the mechanisms that underlie the development of 
insulin resistance and T2DM.  
     Huffman et al. measured various metabolic intermediates (including acylcarnitines, 
amino acids and fatty acids) using mass spectrometry in obese individuals who are at risk 
of T2DM. They found elevated concentrations of these intermediates to be closely related 
to insulin resistance and impaired pancreatic response. 124 Other metabolomics studies 
observed similar findings. In a study done by Newgard et al., mass spectrometry 
techniques were used to analyze and compare plasma samples of lean and obese insulin-
resistant individuals. BCAAs and their metabolites C3 and C5 acylcarnitines, along with 
other amino acids such as glutamine and alanine were strongly correlated with the 
development of insulin resistance. 75 In addition, Suhre et al. found elevated levels of 
metabolic biomarkers of diabetes including sugar metabolites, ketone bodies and BCAAs 
using a multiplatform metabolomics approach in an epidemiological cohort. 125  
     Clinical studies also show positive correlations between increased BCAA levels and 
insulin resistance, HOMA index and HbA1 levels 5,126,127 Shah et al. examined plasma 
samples from 500 overweight/obese subjects at baseline and 6 months after weight loss. 
They used metabolic profiling of 60 metabolites and biochemical assays of ketones, 
insulin, glucose and non-essential fatty acids and found that a metabolite signature that 
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represents BCAA catabolism is associated with insulin resistance and can be improved 
with weight loss 128. Interestingly, Laferrère et al. compared the metabolic effects of two 
methods of weight loss: dietary intervention and gastric bypass surgery in two groups of 
obese type-2 diabetic individuals with identical weight loss. Using mass spectrometry 
metabolomics, they showed that the level of BCAAs and their related metabolites were 
reduced much more significantly after gastric bypass surgery than a dietary intervention 
program resulting in the same amount of weight loss. This indicates that the reduction in 
circulating BCAA levels, improvements in glucose tolerance and BCAA oxidation 
observed in these patients involve mechanisms other than weight loss. 129 Furthermore, 
longitudinal studies in different groups have indicated that increased circulating levels of 
BCAAs predict future insulin resistance and T2DM.7,130 Although such associations are 
repeatedly observed in human models, the mechanisms underlying the relationship 
between high blood BCAA levels and insulin resistance remain to be fully elucidated.  
     So far, two potential mechanisms have emerged that explain how BCAAs may 
contribute to the development of insulin resistance and T2DM. The first mechanism 
suggests that increasing levels of dietary BCAAs results in hyperactivation of the 
mTORC1 pathway which promotes insulin resistance through serine phosphorylation of 
IRS-1. The second mechanism proposes that excess BCAA levels are a biomarker of 
impaired BCAA metabolism, while these impairments could also result in accumulation 
of toxic BCAA metabolites that stimulate β‑cell mitochondrial dysfunction and stress 
signalling associated with insulin resistance and T2DM. 6 Therefore, BCAAs can have 
positive and negative consequences. They are beneficial in increasing muscle mass due to 
their highly anabolic effects, but can also exert negative effects on insulin signalling and 
cause insulin resistance.  Thus, further studies are needed to fully understand their 
mechanism of action and implication in insulin resistance and T2DM. 
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2.8 Rationale 
      Despite the growing research on the effect of high protein/leucine diets on mTORC1 
activation and implications in insulin resistance, current evidence on the exact molecular 
mechanism that mediates these effects still remains inconclusive. Although BCAAs and 
their metabolites have been shown to be implicated in the development of insulin 
resistance and T2DM 7,8,17, some studies suggest beneficial roles of high protein/BCAA 
levels in improving insulin sensitivity and glucose uptake in skeletal muscle 65,68,119,131–
133. Thus, it is imperative to understand how leucine and its metabolites regulate glucose 
transport and mTORC1/S6K1 signalling in skeletal muscle since it is the predominant 
tissue for insulin-induced glucose disposal. Most studies that have examined glucose 
transport and mTORC1 signalling in response to leucine treatment in skeletal muscle 
have tested supraphysiological concentrations of leucine, which do not correlate with 
normal physiological levels. Therefore, it is important to determine the effect of leucine 
in a concentration range that is more physiologically relevant. Furthermore, under normal 
circumstances, leucine is consumed along with other amino acids; therefore, it is also 
essential to understand the effect of leucine on glucose transport and mTORC1 signalling 
in the presence of other amino acids.  
Moreover, it is not exactly known whether the effects observed with leucine on glucose 
transport in-vitro are due to its intracellular catabolism. More specifically it is not known 
whether leucine metabolite KIC can independently regulate insulin sensitivity in L6 
myotubes.  
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2.9 Objective 
1) Examine the molecular mechanisms that mediate the effect of leucine supplementation 
on insulin-stimulated glucose uptake and mTORC1 pathway activation in L6 rat skeletal 
muscle cells. More specifically, determine whether leucine’s effect is dose-dependent, 
using physiologically relevant concentrations. 
2) Examine the dose-dependent effect of leucine on insulin-induced glucose uptake and 
mTORC1 signalling in the presence of other amino acids.  
3) Determine the effect of KIC treatment on insulin-stimulated glucose transport and 
mTORC1 signalling in L6 myotubes. 
4) Examine whether KIC-mediated regulation of glucose transport and mTORC1 activity 
is independent of its intracellular conversion to leucine  
 
3.0 Hypothesis 
      I hypothesize that leucine treatment will suppress insulin-stimulated glucose transport 
in skeletal muscle through increased activation of mTORC1/S6K1 signalling. I also 
hypothesize that KIC can exert similar effects on insulin-stimulated glucose uptake and 
mTORC1 signalling in L6 myotubes. Finally, I hypothesize that KIC-mediated regulation 
of insulin signalling and mTORC1 pathway is at least in part due to its intracellular 
conversion back to leucine.  
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Figure 1. General overview of insulin signalling pathway and proteins 
involved in glucose transport  
 
Insulin binds to the insulin receptor leading to activation of the receptor and thus tyrosine 
phosphorylation of the insulin receptor substrate 1 (IRS-1). This causes IRS-1 to interact with 
phosphatidylinositol-3-kinase (PI3K), facilitating the conversion of phosphatidylinositol-4, 5-
bisphosphate (PIP2) to phosphatidylinositol-3, 4, 5-triphosphate (PIP3). PIP3 then allows the 
recruitment of other kinases such as PDK1, which phosphorylates Akt. Upon its activation, Akt 
phosphorylates and inhibits Akt substrate of 160 kD (AS160), thereby allowing the translocation 
of GLUT4 to the plasma membrane and leading to glucose uptake into the cell. In addition, Akt 
activates mTORC1 by phosphorylating TSC1/2 and removing its inhibitory restraint on Rheb. 
Amino acids can directly activate mTORCl through the Ragulator complex on the lysosomal 
surface which acts as a docking site for Rag GTPases. When mTORC1 is recruited to the 
lysosomal membrane, it interacts with Rheb in its GTP-bound form and it becomes activated.  
Figure adapted from “Insulin resistance in the nervous system”, by B. Kim and E. L. Feldman, 
2012, Trends in Endocrinology and Metabolism, 23, 133-141.  
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Figure 2. Defective insulin signalling as a result of excess amino acid 
levels 
 
Amino acids (particularly leucine) are potent stimulators of mTORC1 activity. Thus, 
amino acid overload can result in hyperactivation of mTORC1, leading to the formation 
of a negative feedback loop from S6K1 to IRS-1. Phosphorylation of IRS-1 on serine 
residues instead of the normal tyrosine residues leads to inhibition of its function and its 
degradation. This defect in insulin signalling pathway can ultimately result in insulin 
resistance and inhibition of glucose uptake. 
Figure adapted from “Upstream of the mammalian target of rapamycin: do all roads pass 
through mTOR?”, by M. N. Corradetti and K. L. Guan, 2006, Oncogene, 25, 6347–6360. 
 
 
  37 
4.0 Manuscript 
 
 
 
 
 
Leucine and its metabolite, α-ketoisocaproic acid, suppress 
insulin-stimulated glucose transport in L6 myotubes 
 
 
Mahshid Moghei 1, Olasunkanmi A.J. Adegoke 1 
 
 
Muscle Health Research Centre, School of Kinesiology and Health Science, 
York University, Toronto, ON, M3J 1P3 
 
 
Corresponding Author: Dr. Olasunkanmi A.J. Adegoke  
Muscle Health Research Centre, School of Kinesiology and Health Science, York 
University, Toronto, ON, Canada. Tel: 416-7362100 Ext 20887. Fax: 416-736-
5774. Email: oadegoke@yorku.ca 
 
 
Key words: Insulin resistance, skeletal muscle, glucose transport, leucine, KIC, 
mTORC1,  
 
 
 
 
 
 
 
 
  38 
Introduction 
 
     Type 2 diabetes mellitus (T2DM) is a global health concern and a major risk factor for 
morbidity and mortality. It is preceded by a condition known as insulin resistance which 
is characterized by a reduction in the body’s sensitivity to the hormone insulin. 4 Many 
factors can contribute to the development of insulin resistance and T2DM with nutrition 
being one of the major ones. In addition to high fat diets, high protein diets have recently 
been shown to be closely associated with the development of insulin resistance and 
T2DM.8  
     Branched-chain amino acid (BCCAs) are often used for their positive effects in 
metabolic health They have many positive effects such as regulation of body weight, 
muscle protein synthesis and glucose homeostasis.6 Therefore, BCAA supplementations 
are often used for weight loss in people with obesity. Among all three BCAAs, leucine 
has the strongest effect on muscle protein synthesis through the activation of the 
mammalian/mechanistic target of rapamycin complex 1 (mTORC1). Recently, studies 
have suggested that despite their beneficial effects, high concentrations of plasma 
BCAAs are associated with a higher risk of T2DM. This has been supported by studies in 
human and rodent models which found elevated level of circulating BCAAs and their 
metabolites in the plasma of insulin resistant/Type-2 diabetic subjects. Hyperactivation of 
the mTORC1 pathway and the subsequent impairment of normal insulin receptor 
substrate-1 (IRS-1) function has been shown as a mechanism contributing to the 
development of insulin resistance and T2DM.5–7,130 In contrast, other studies have shown 
benefits of BCAAs, particularly leucine, in stimulating glucose transport and improving 
insulin sensitivity in skeletal muscle. 68,119,132,133 Therefore, it is not exactly known how 
BCAAs may be involved in the development of insulin resistance and T2DM. The 
objectives of this study were to examine the dose-dependent effect of leucine on insulin-
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stimulated glucose uptake in the presence or absence of other amino acids in L6 skeletal 
muscle cells. We also examined how leucine metabolite, α-ketoisocaproic acid (KIC), 
affects glucose transport and mTORC1 signalling in control and in cells where BCAT2 
(branched-chain aminotransferase 2 mitochondrial) enzyme has been depleted. This 
enzyme catalyzes the reversible transamination of leucine to KIC. We found that leucine 
significantly impairs insulin-stimulated glucose transport, concurrent with increased 
mTORC1 activation, suggesting a link between impaired insulin signalling and mTORC1 
activity. KIC was also found to inhibit insulin-stimulated glucose transport through 
upregulation of mTORC1 activity. Interestingly, depleting the BCAT2 enzyme attenuates 
the inhibitory effect of KIC on insulin-induced glucose transport, suggesting that in fact it 
is the intracellular conversion of KIC to leucine which causes the impairment of glucose 
transport. Our results suggest that leucine and KIC impair insulin-stimulated glucose 
transport in L6 myotubes and therefore, may be implicated in the development of insulin 
resistance and T2DM. 
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5.0 Materials and Methods 
 
 
5.1 Reagents  
The growth medium (GM) used for cell growth was α- Modification of Eagle’s Medium 
(AMEM) purchased from Wisent (#310-010-CL), supplemented with 10% fetal bovine 
serum (FBS) (Gibco #26050-088) and 1% Antibiotic-Antimycotic (Wisent #450-115-
EL). Phosphate Buffered Saline (PBS) and Trypsin were also purchased from Wisent. 
The medium used for differentiation of cells (DM) consisted of AMEM, 1% antibiotic-
antimycotic and 2% horse serum (HS) (Gibco #26050088). RPMI 1640 (a medium free 
of amino acids and serum) was used as the starvation medium and was purchased from 
United States Biologicals (#R8999-04A). L-Leucine (#61-90-5) and Sodium 4-methyl-2-
oxovalerate (KIC) (#K0629) were purchased from Sigma Aldrich. RPMI 1640 without 
leucine (a medium containing all amino acids except leucine) was used for leucine dose-
dependent experiment in the presence of other amino acids and was purchased from 
United States Biologicals (#R8999-12). BCAT2 (#111-125) and scramble (negative 
control) siRNA (#S1452) oligosachharides were purchased from Sigma-Aldrich. 
Lipofectamine RNAiMAX was purchased from Life technologies (#13778-150). Opti-
MEM 1X Reduced Serum Medium was purchased from Life Technologies (#31985-070). 
Immobilon Western HRP chemiluminescence substrate was obtained from Fischer-
Scientific (#WBKLS0500). [3H]-2-deoxyglucose was purchased from Perkin Elmer 
(#NET549).   
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5.2 Cell Culture  
L6 rat skeletal muscle myoblasts were purchased from American Type Culture 
Collection. Cells cells were cultured in 10 cm plates with growth medium composed of 
AMEM supplemented with 10% FBS and 1% Antibiotic-Antimycotic and allowed to 
propagate at 37°C and 5% CO2 in a cell culture incubator until they reached ~ 80% 
confluency. Next, they were counted and seeded at a density of 2x105/well in either 6-
well plates for western blot experiments (described in section 3.5) or 105 cells/well for 
12-well plates for glucose transport (described in section 3.3). Cells were allowed to 
proliferate for 48 hours or until they became confluent. Following the incubation period, 
the medium was switched to DM every 48 hours and cells were allowed to differentiate 
into myotubes until D5 when the experiments were performed (Description below). 
 
5.3 Glucose Transport Assay 
 
     Glucose uptake assay, a measure of insulin action, was performed using radiolabeled 
2- deoxyglucose (2-DG). When 2-DG is taken up by glucose transporters, it is 
phosphorylated to 2-DG-6-phosphate (2-DG6P); however, it cannot be further 
metabolized and therefore accumulates in the cell. The addition of radiolabeled glucose 
([3H]-2-deoxyglucose) as the tracer to 2-DG in the transport solution allows for the entry 
of the radioactively tagged glucose into the cells along with normal 2-DG glucose. 134 
Therefore, we can measure the level of glucose uptake by determining the amount of 
radioactivity present in the cell.  
     On Day 5 of differentiation, myotubes were starved for 4 hours in RPMI (complete 
starvation medium, free of amino acids and serum). Following the starvation period, 
myotubes were treated with the first treatment, either RPMI (without amino acids and 
serum) or RPMI (containing all other amino acids except leucine) in which leucine was 
  42 
added at various concentrations (150, 350, 600, 800 and 1800 μM) for 30 minutes. For 
the KIC experiment, following the 4 hr starvation, myotubes were treated with RPMI 
(free of amino acids and serum) containing two different concentrations of KIC (200 and 
400 μM) for 30 minutes. Subsequently, the incubation with leucine or KIC continued in 
the presence or absence of 100 nM of insulin for 20 minutes. The cells were then rinsed 
twice with HEPES (4-(2-Hydroxyethyl) piperazine-1-ethanesulfonic acid) buffered 
saline, which is an organic chemical buffering agent. They were then incubated in 300 μL 
of transport solution (HEPES buffer, 10μM 2-deoxyglucose, 0.5 μCi/mL [3H]-2-
deoxyglucose) for 5 minutes at 37°. Following the 5-minute incubation period, the 
transport solution was removed and the cells were immediately rinsed with ice-cold stop 
solution (0.9% Saline) three times to stop the reaction and prevent any further glucose 
uptake. Subsequently, 1mL of 0.05M NaOH was added to each well and the cells were 
scraped and collected on ice. Samples were then stored at -20°C for further analysis. 
During analysis, 200 μL of each sample was used to conduct protein assay and the 
remaining 800 μL was added to 4-5 mL of Scintillation fluid (Ecolite+, MP Biomedicals 
#01882475) in liquid scintillation vials. The amount of radioactivity in each sample was 
counted using a Liquid Scintillation Counter (Tri-Carb Liquid Scintillation Counter). 
Rate of glucose transport was expressed per μg of protein. (See Appendix A and B) 
 
5.4 siRNA Gene Silencing 
L6 myoblasts were plated in 6-well plates at a density of 2x105 cells/ well. After 48 hours, 
medium was shifted to DM. On day 3 of differentiation, myotubes 
were transfected with 50 nM of BCAT2 siRNA or 50 nM of scramble siRNA (negative 
control) using Lipofectamine RNAiMAX reagent according to the manufacturer’s 
instructions (Life technologies). Lipofectamine RNAiMAX reagent was diluted in Opti-
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MEM medium. BCAT2 siRNA and the scramble siRNA were diluted in Opti-MEM 
medium. Next diluted siRNAs were added to diluted Lipofectamine RNAiMAX reagent 
in 1:1 ratio and were allowed to incubate for 5 minutes at room temperature. Finally, 250 
µL of the siRNA-lipid complex was added to respective wells containing 1mL of 
antibiotics-free a-MEM with 2% HS. Twenty four hours following transfection, 1mL of 
a-MEM containing 2% HS and 1% Ab-Am was added to each well. On day 5 of 
differentiation (48 hours following transfection) some cells were harvested to test the 
efficiency of the BCAT2 knockdown using immunoblot analysis. The remaining wells 
were either used for glucose transport assay (refer to section 5.3) or western blot analysis 
(refer to section 5.5). (See Appendix A and C) 
 
5.5 Cell Harvesting for Western Blot Analysis 
     Following the treatments, cells were rinsed with PBS. Then 100 μL of lysis buffer 
[1mM EDTA, 2% sodium dodecyl sulphate (SDS), 25 mM Tris-HCL pH 7.5, 10μL/mL 
protease inhibitor (Sigma Aldrich #P8340), 10μL/mL phosphatase inhibitor (Sigma 
Aldrich # P5726) and 1mM DTT (Research Organics #2190D-A101X) was added to each 
well of the 6-well plate. The cells were then scraped and transferred into 1.5 mL 
Eppendorf tubes using a 1mL Syringe. Repeated aspiration and expulsion was used to 
ensure breakdown of the cell lysate. Cells were stored at -20°C for further analysis. 
 
5.6 Protein Assay and Western Blot Analysis 
The Pierce BCA Protein Assay Kit (Thermo Scientific #23225) was used to determine 
protein concentration. The KC4 plate reader software (Bio-Tek Instruments Inc.) was 
used to obtain an absorbance reading of each well at a wavelength of 550 nanometers. A 
standard curve was used to estimate the volume required to load 25 μg of protein into one 
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well of a polyacrylamide gel. Equal amounts of protein were loaded into each well of the 
gel. The proteins were separated on 10% SDS-polyacrylamide gel electrophoresis (SDS-
PAGE). Following gel electrophoresis, they were transferred onto polyvinylidene 
difluoride (PVDF) membranes. Next, membranes were incubated for one hour in 5% 
non-fat milk in Tris Buffered Saline with Tween (TBST) at room temperature to block 
non-specific antigen binding. Subsequently, they were quickly rinsed 3 times with TBST 
for 5 minutes and then incubated overnight at 4°C with the desired primary antibody.  
Primary antibodies: ph-S6K1Th389 1:1000 dilution (Cell Signalling #9205), ph-IRS-1Ser612 
1: 1000 dilution (Cell Signalling #3203), ph-S6 Ser 235/236 1:1000 dilution (Cell Signalling 
# 4858), Gamma-Tubulin 1:10000 dilution (Sigma Aldrich #T6557). BCAT2 1:1000 
dilution (Sigma Aldrich #111-125).  
 Following the overnight incubation in primary antibody, membranes were quickly rinsed 
2 times and 3 times for 5 minutes each with TBST and then incubated in secondary 
antibody for three hours at room temperature.  
Secondary Antibodies: Anti-rabbit (CST # 7074) and Anti-mouse (CST #7076) 
antibodies were used with the dilution of 1:10000. Subsequently, membranes were rinsed 
again 3 times for 5minutes each with TBST before HRP chemical luminescent substrate 
was applied to them. Kodak molecular imaging system was used for signal visualization 
and the images were quantified with Carestream molecular imaging software (version 5 
.0.3.33) 
 
 
 
 
 
  45 
4.7 Graphical Representations of Glucose Transport and Western Blots 
Glucose transport data is normalized to the control group with no amino acid, KIC or 
insulin (CTL-insulin). This was done by dividing the amount of [3H]-2-deoxyglucose 
(pmol) transported into cells in each well by the concentration of protein found in each 
well (µg). The glucose transport value (pmol/µg) was then expressed as percentage of 
glucose transport in myotubes that were not treated with amino acid, KIC or insulin. 
Western blots for ph-S6K1, ph-IRS-1 and ph-Akt were normalized to the control group 
which was not treated with amino acid or KIC, but treated with insulin (CTL+ins)   
 
4.8 Statistical Analysis  
Statistical analyses were performed using GraphPad Prism 5 software. Data presented 
here are means ± SEM. One-way analysis of variance (ANOVA) was used and Tukey’s 
post-hoc tests were done to measure statistically significant differences among means. 
Two-tailed T-tests were also performed to measure difference between two groups (ie. 
+ins vs –ins). Significance was determined as p <0.05. Bars with different letters are 
significantly different. Letters shared among groups indicate they are not significantly 
different. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  46 
6.0 Results 
 
 
The effect of leucine on glucose transport in the presence of other amino 
acids  
 
Since dietary proteins contain amino acids other than leucine, we sought to determine 
how the presence of other amino acids (medium composition) affects insulin-stimulated 
glucose uptake in L6 cells. We tested the dose-dependent effect of leucine in a medium 
that contains all the other amino acids but leucine. Since most studies in the literature 
have worked with supraphysiological concentrations of leucine, we chose to work with 
concentrations that are within a physiologically relevant range (0-1600 µM). In the 
presence of other amino acids, leucine does not significantly alter insulin-stimulated or 
basal glucose transport levels relative to control. The insulin effect within the control 
group was 100%, while for other concentrations of leucine it ranged from 24-48%, 
suggesting that in the presence of other amino acids, the effect of insulin becomes weaker 
since basal glucose uptake is higher compared to control (Fig 4) 
  
The effect of medium composition (presence of other amino acids) on 
leucine-mediated stimulation of mTORC1 
 
To determine how the presence of other amino acids affects leucine-mediated stimulation 
of mTORC1 signalling and examine if the effects observed with glucose transport are 
mediated through mTORC1 activation, we examined the phosphorylation levels of 
proteins involved in the mTORC1 pathway. Leucine treatment in a medium containing all 
other amino acids significantly promotes basal and insulin-stimulated phosphorylation of 
S6K1T389 at all concentrations tested relative to control (p <0.05). Insulin-stimulated 
levels of ph-S6K1T389 are increased by about 40-65% relative to control while basal 
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levels are higher by about 2.5-4 fold compared to control. Interestingly, within the control 
group, insulin caused a 9X increase in ph-S6K1T389 levels, while in the treatment groups 
the insulin effect ranged from 1.5-3 folds. Insulin-stimulated and basal phosphorylation 
of IRS-1Ser612 also show a trend for a dose-dependent increase relative to control, although 
non-significantly. Insulin caused a 3X increase in ph-IRS-1Ser612 in the control group, 
whereas within the other treatment groups, the effect of insulin ranged from 80-140%. 
Therefore, leucine promotes basal and insulin-stimulated phosphorylation of mTORC1 
pathway proteins and more importantly, in the presence of other amino acids, basal levels 
of ph-S6K1T389 and IRS-1Ser612 are higher relative to control (Fig 5) 
 
The effect of leucine alone on glucose uptake in L6 myotubes 
 
To determine whether leucine, independent of other amino acids, can regulate glucose 
transport, we examined the dose-response effect of leucine at 150, 350, 600, 800 and 
1600 μM. There is an overall inhibitory effect of leucine treatment (at all concentrations) 
on insulin-stimulated glucose transport relative to control (p<0.05). However, the effect is 
stronger at 150 μM, where there is a 75% reduction in insulin-stimulated glucose 
transport relative to control (p <0.01). We did not observe a significant difference in basal 
levels of glucose uptake across all treatments. The insulin effect within the control group 
was 110% while in the treatment groups it ranged from 40-70%, indicating that in the 
presence of leucine, the effect of insulin on glucose transport is less evident. It appears 
that the inhibitory effect of leucine on insulin-induced glucose uptake becomes less 
pronounced at higher concentrations, suggesting that there might be a positive shift in 
glucose uptake levels in response to leucine and insulin at concentrations much higher 
than physiological levels.  (Fig 6) 
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Dose-dependent effect of leucine on mTORC1 activation in L6 myotubes 
 
To understand whether leucine-mediated suppression of glucose transport occurs via 
increased mTORC1 pathway activation and whether its effects are dose-dependent, we 
treated myotubes with various concentrations of leucine (150, 350, 600, 800 or 1600 μM) 
and then examined mTORC1 signalling. Leucine in the presence of insulin, stimulates 
mTORC1 activation in a dose-dependent manner. This is observed by the significant 
upregulation of S6K1T389 phosphorylation with increasing leucine concentrations 
(p<0.05). Interestingly, the basal levels of ph- S6K1T389 are barely detectable, suggesting 
that the combined effect of leucine and insulin on mTORC1 activation is much more 
potent than leucine alone. This is expected since both leucine and insulin are powerful 
signaling inputs that activate mTORC1. Furthermore, there is a trend for a non-significant 
upregulation in insulin-stimulated ph-IRS-1Ser612 levels, while basal levels are barely 
detectable. Overall, our results demonstrate that leucine impairs insulin signalling 
through increasing mTORC1 activation. (Fig 7) 
 
Basal Glucose Uptake is Higher in the Presence of Other Amino Acids 
 
Since basal levels of glucose uptake appeared to be higher in our first experiment carried 
out in the presence of other amino acids (Fig 3), compared to our second experiment 
where the role of leucine alone on glucose transport was examined (Fig 5), we used these 
data to compare basal glucose uptake levels in a medium without amino acids versus a 
medium that contains all amino acids. When a combination of amino acids is present in 
the medium, basal glucose uptake rate is significantly higher compared to when there are 
no amino acids in the medium. Insulin-stimulated glucose transport is also higher in the 
presence of all amino acids, although non-significantly. Interestingly, in the presence of a 
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combination of amino acids, insulin increases glucose uptake by about 90%, while in the 
absence of amino acids, the effect of insulin is 120%. Therefore, the magnitude of insulin 
effect is smaller in the presence of amino acids, meaning that the basal levels are already 
so high, such that the availability of insulin will not significantly alter glucose uptake 
levels. These results demonstrate that an amino acid mixture enhances basal glucose 
uptake levels in skeletal muscle cells, particularly in the absence of insulin, indicating 
there might be pathways other than the PI3K-Akt signalling pathway involved in amino 
acid-mediated glucose transport. (Fig 8) 
 
The effect of KIC on glucose transport and insulin signalling in L6 
myotubes  
 
Since KIC is a metabolite of leucine and it has been shown to be involved in mTORC1 
pathway activation, we were interested in examining whether it has a similar effect to 
leucine on glucose transport. Furthermore, the role of KIC in insulin-stimulated glucose 
transport has not been examined in a physiologically-relevant concentration range. We 
tested the effect of KIC treatment on insulin-stimulated glucose transport at 200 and 400 
μM in L6 cells to mimic upper-range physiological levels and to see if there is a dose-
dependent effect. Supplementation with 200 μM of KIC suppresses insulin-mediated 
glucose transport by 45% (p<0.05). It also causes a non-significant suppression of basal 
glucose transport at this concentration. The magnitude of insulin effect within the control 
group is similar to the treatment groups (55-60%). (Fig 9) 
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Treatment with KIC results in activation of mTORC1/S6K1 pathway 
 
To determine whether the effect of KIC on glucose transport is associated with changes 
in the mTORC1 pathway activity, phosphorylation of three major proteins involved in the 
mTORC1 pathway were examined: S6K1T389, IRS-1Ser612 and Akt Ser473. We chose to 
examine Akt activity because growth factor-mediated activation of mTORC1 occurs via 
Akt 14,94. Moreover, we tested the effect of KIC on mTORC1 signalling at two different 
concentrations, 200 and 400 μM to try to mimic upper-range physiological levels and to 
see if there is a dose-dependent effect. KIC treatment at 200 μM significantly stimulates 
mTORC1 activity as shown by a 125% increase in ph-S6K1T389 and a 55% increase in 
ph-IRS-1Ser612 levels. Supplementation with KIC at 400μM also caused a non-significant 
upregulation in ph-S6K1T389 and ph-IRS-1Ser612  levels. However, KIC treatment did not 
significantly modulate phosphorylation level of Akt Ser473 possibly because Akt activation 
is dependent on the insulin-mediated PI3K pathway rather than KIC-mediated mTORC1 
activation, therefore, the presence of KIC in the medium may mask the full effect of 
insulin on Akt activation. Our results suggest that leucine metabolite KIC, can also 
stimulate mTORC1 activity similar to leucine. (Fig 10) 
 
KIC-mediated regulation of glucose transport involves mTORC1 
 
Since suppression of glucose transport by KIC occurred in parallel with increased 
mTORC1 activity, I examined whether rapamycin, a specific inhibitor of mTORC1, 
could ameliorate the KIC-mediated suppression of glucose transport. As shown before, 
200 μM of KIC suppressed insulin-stimulated glucose transport by 40%. (p <0.05) 
However, co-incubation of 50 nM of rapamycin and 200μM of KIC reversed the 
inhibitory effect of KIC on glucose transport (p <0.05). The magnitude of insulin effect is 
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higher in the control group where insulin increased glucose uptake by 75% while in the 
treatment groups the effect of insulin ranged from 30-45%. These results demonstrate the 
involvement of mTORC1 in KIC-mediated regulation of glucose transport and that 
inhibition of mTORC1 reverses the negative effects of KIC on glucose transport. (Fig 11) 
 
The effect of rapamycin on KIC-mediated regulation of mTORC1 
 
To link the effect of rapamycin on KIC-induced suppression of insulin-stimulated glucose 
transport to mTORC1, we measured ph-S6K1T389, ph-S6Ser235/236 and ph-IRS-1Ser612 levels. 
As expected, rapamycin significantly inhibited phosphorylation of ph-S6K1T389, ph-IRS-1 
Ser612, and ph-S6Ser235/236 (p<0.05). KIC-mediated stimulation of mTORC1 activity is 
inhibited in the presence of rapamycin, as shown by the reduced phosphorylation levels 
of IRS- Ser612 and S6Ser235/236 in the presence of rapamycin. We did not observe ph-
S6K1T389 levels in in the co-incubation of rapamycin and KIC. This could be due to the 
particularly strong inhibition of rapamycin on phosphorylation of S6K1 such that even 
the presence of insulin and KIC was not sufficient to activate S6K1. (Fig 12) 
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KIC-mediated suppression of glucose transport is due to its intracellular 
conversion to leucine 
 
Since the first step in the catabolism of leucine to its metabolite KIC, is reversible, one 
could speculate that the KIC-mediated inhibition of insulin-stimulated glucose transport 
is because KIC is being converted to leucine and that these negative effects are caused by 
leucine and not KIC. To our knowledge, the effect of KIC itself on insulin-stimulated 
glucose transport in L6 myotubes has not been examined. Therefore, we used an siRNA 
gene silencing technique to knockdown the BCAT2 enzyme that catalyzes the reversible 
conversion of leucine to KIC. By doing this, we aimed to “block” the intracellular 
conversion of KIC to leucine and then examine whether KIC can independently regulate 
glucose transport and mTORC1 activation in skeletal muscle cells. We knocked down the 
BCAT2 enzyme in our L6 cells and then supplemented them with KIC in the presence or 
absence of insulin. Depletion of the BCAT2 enzyme, attenuates the KIC-mediated 
suppression of insulin-induced glucose transport (p<0.05), indicating the observed effects 
are due to the conversion of KIC back to leucine. The magnitude of insulin effect in all 
treatment groups was similar to control, ranging from 45% to 60%. Therefore, it appears 
that KIC cannot independently regulate glucose transport in L6 myotubes and that its 
effects are mainly caused by its reversible conversion to leucine. (Fig 13 A)  
The efficiency of BCAT2 knockdown is demonstrated in Fig 13 B. 
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The effect of BCAT2 knockdown on KIC-mediated regulation of 
mTORC1 pathway 
 
We observed that the inhibitory effect of KIC on glucose transport is due to its 
intracellular conversion to leucine. Now, we wanted to determine whether KIC-mediated 
regulation of the mTORC1 pathway also depends on its conversion to leucine. We 
knocked down the BCAT2 enzyme and then examined the effect of KIC supplementation 
on mTORC1 pathway activation. Interestingly, we observed that depleting the BCAT2 
enzyme significantly suppresses the KIC-mediated activation of mTORC1 (p<0.05) as 
shown by the phosphorylation levels of S6K1T389, IRS-1S612 and AktS473. This further 
supports the notion that conversion of KIC to leucine is required for its regulation of 
insulin signalling and mTORC1 activation. (Fig 14)  
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7.0 Figures  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4. Glucose uptake rate in response to different leucine concentrations in the 
presence of other amino acids  
 
L6 myoblasts were differentiated until day 5. On D5, they were starved for 4 hours in RPMI 
(without amino acids and serum). They were then incubated in a medium that contained all amino 
acids except leucine and then supplemented with different [leucine] for 30 minutes. Finally, the 
myotubes were incubated for another 20 minutes in the presence or absence of 100 nM of insulin. 
Glucose uptake assay was then performed. Rate of glucose transport is expressed as % CTL (no 
amino acids or insulin). Mean ± SEM; n=3 independent experiments with 3-6 replicates per 
treatment within each experiment. 
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a)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5. Leucine-mediated activation of mTORC1 in the presence of other amino acids 
 
Graphical representation and western blot analysis of a) ph-S6K1T389, b) ph-IRS1 Ser612 and 
gamma tubulin. L6 myoblasts were differentiated until D5. On D5, they were starved for 4 hours 
in RPMI (without amino acids and serum). They were then incubated in a medium that contained 
all amino acids except leucine and then supplemented with different [leucine] for 30 minutes, 
followed by a 20-minute incubation in the presence or absence of 100 nM of insulin. Lastly, 
samples were harvested for immunoblot analysis. Data is presented as % CTL (no amino acids 
+ins). Mean ± SEM; n=3 independent experiments with 3-6 replicates per treatment within each 
experiment (p <0.05). 
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Fig 6. Leucine impairs insulin-stimulated glucose transport in L6 myotubes 
 
L6 myoblasts were differentiated for 5 days. On D5, they were starved for 4 hours in RPMI 
(without amino acids and serum) and then treated with different leucine concentrations for 30 
minutes. They were then incubated in the presence or absence of 100 nM of insulin for 20 
minutes. Glucose uptake assay was then performed. Rate of transport is expressed per μg of 
protein. Rate of glucose transport is expressed as % CTL (no amino acids or insulin). Mean ± 
SEM; n=4 independent experiments with 3-6 replicates per treatment within each experiment.  
(p< 0.05).  “a” significantly different from “b” (p<0.01). 
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a)  
 
 
 
 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
 
 
 
Fig 7. Leucine impairs glucose transport via upregulation of mTORC1 activity 
 
Graphical representation and western blot analysis of a) ph-S6K1 T389, b) ph-IRS1 S612 and gamma 
tubulin. L6 myoblasts were differentiated until day 5. On D5, following 4 hours of starvation in 
RPMI (without amino acids and serum), they were incubated with various leucine concentrations 
for 30 minutes. They were then incubated in the presence or absence of 100 nM of insulin for 20 
minutes. Lastly, samples were harvested for immunoblot analysis. Data is expressed as % CTL 
(no amino acids +insulin). Mean ± SEM; n=3 independent experiments with 3-6 replicates per 
treatment within each experiment. Bars with different letters are significantly different (p<0.05).  
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a)                                                                           b) 
 
      
 
 
Fig 8. An amino acid mixture enhances basal glucose uptake rate and ph-S6K1T389 
levels in L6 myotubes 
 
Derived from data in Figure 3 and Figure 5.  
L6 myoblasts were differentiated for 5 days. On D5, they were starved for 4 hours in RPMI 
(without amino acids and serum) and then incubated in a medium that contained either all amino 
acids, or no amino acids at all for 30 minutes. They were then incubated in the presence or 
absence of 100 nM of insulin for 20 minutes. Glucose uptake assay was then performed. Rate of 
transport is expressed per μg of protein. Mean ± SEM; n=3 independent experiments with 3-6 
replicates per treatment within each experiment. Bars with different letters are significantly 
different (p < 0.05).   
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Fig 9. Supplementation with 200μM of KIC significantly suppresses insulin-
stimulated glucose uptake in L6 cells  
 
L6 myoblasts were differentiated until day 5. On D5, following 4 hours of starvation in RPMI 
(without amino acids and serum), they were treated with 200 or 400 μM of KIC for 30 minutes. 
They were then further incubated in the presence or absence of 100 nM of insulin for 20 minutes. 
Glucose uptake assay was then performed. Rate of transport is expressed per μg of protein. Rate 
of glucose transport is expressed as % CTL (no amino acids or insulin). Mean ± SEM; n=4 
independent experiments with 3-6 replicates per treatment within each experiment. Bars with 
different letters are significantly different (p <0.05). 
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Fig 10. The role of KIC in mTORC1/S6K1 pathway activation  
 
Graphical representation and western blot analysis of a) ph-S6K1T389, b) ph-IRS-1 Ser612, c) ph-
Akt Ser473 and gamma tubulin. L6 myoblasts were differentiated until D5. On D5, following 4 
hours of starvation in RPMI (free of amino acids and serum), myotubes were incubated with 
different [KIC] for 30 minutes. They were then incubated in the presence or absence of 100 nM 
of insulin for 20 minutes. Samples were then harvested for immunoblot analysis. Data is 
expressed as % CTL (no KIC +insulin). Mean ± SEM; n=3 independent experiments with 3-6 
replicates per treatment within each experiment. Bars with different letters are significantly 
different (p< 0.05).  
 
 
a) b) 
c) 
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Fig 11. KIC-mediated suppression of glucose transport involves mTORC1 
 
L6 myoblasts were differentiated until day 5. On D5, following 4 hours of starvation in RPMI 
(free of amino acids and serum), myotubes were supplement with either KIC, KIC plus 50 nM of 
rapamycin, or 50 nM of rapamycin for 30 minutes. They were then incubated in the presence or 
absence of 100 nM of insulin for another 20 minutes. Glucose uptake assay was then performed 
to determine the level of glucose uptake. Rate of glucose transport is expressed as % CTL (no 
KIC or insulin). Mean ± SEM; n=3 independent experiments with 3-6 replicates per treatment 
within each experiment. Bars with different letters are significantly different (p<0.05).  
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Fig 12. The effect of rapamycin on KIC-mediated activation of mTORC1 
 
Graphical representation and western blot analysis of a) ph-S6K1T389 and b) ph-IRS-1 Ser612, c) ph-
S6Ser235/236 and gamma tubulin. L6 myoblasts were differentiated until day 5. On D5, following 4 
hours of starvation in RPMI (free of amino acids and serum), myotubes were supplement with 
either 200µM of KIC alone, 200µM KIC plus 50 nM of rapamycin, or 50 nM of rapamycin for 30 
minutes. They were then incubated in the presence or absence of 100 nM of insulin for 20 
minutes. Samples were then harvested for immunoblot analysis. Data is expressed as % CTL (no 
KIC +insulin). Mean ± SEM; n=3 independent experiments with 3-6 replicates per treatment 
within each experiment. Bars with different letters are significantly different (p< 0.05).  
a)  b)  
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Fig 13. BCAT2 knockdown attenuates the inhibitory effect of KIC on glucose 
transport 
 
L6 myoblasts were differentiated until day 3. On D3, they were transfected with siRNA targeting 
the BCAT2 enzyme or scramble siRNA. They were then allowed to differentiate further until day 
5. On D5, samples were either harvested for immunoblot analysis a) or b) following 4 hours of 
starvation in RPMI (free of amino acids and serum), myotubes were supplement with or without 
200 µM KIC for 30 minutes. They were then incubated in the presence or absence of 100 nM of 
insulin for another 20 minutes. Glucose uptake assay was then performed. Rate of glucose 
transport is expressed as % CTL (SCR siRNA, no KIC, no insulin). Mean ± SEM; n=3 
independent experiments with 3-6 replicates per treatment within each experiment. Bars with 
different letters are significantly different (p<0.05).  
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Fig 14. The effect of BCAT2 knockdown on KIC-mediated regulation of mTORC1  
 
Graphical representation and western blot analysis of a) ph-S6K1T389, b) ph-IRS-1 Ser612, c) ph-
Akt Ser473 and gamma tubulin. L6 myoblasts were differentiated until D3. On D3, they were 
transfected with siRNA targeting the BCAT2 enzyme or scramble siRNA. They were then 
allowed to differentiate further until day 5. On D5, following 4 hours of starvation in RPMI (free 
of amino acids and serum), myotubes were supplement with or without 200 µM of KIC for 30 
minutes, followed by another 20-min incubation in the presence or absence of 100 nM of insulin. 
Samples were then harvested for immunoblot analysis. Data is expressed as % CTL (no KIC 
+insulin). Mean ± SEM; n=3 independent experiments with 3-6 replicates per treatment within 
each experiment. Bars with different letters are significantly different (p<0.05).  
a) b) 
c) 
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8.0 Discussion  
 
 
     We used an in-vitro model to examine the effect of leucine and its metabolite KIC on 
insulin-stimulated glucose transport. My first experiment was examining the effect of 
different leucine concentrations on glucose uptake and mTORC1 activation in the 
presence of other amino acids. This is because most dietary proteins that people consume 
for weight loss or building muscle mass contain other amino acids in addition to leucine. 
Thus, we sought to determine how the availability of other amino acids affects leucine’s 
regulation of glucose uptake and mTORC1 signalling. In a medium that contains all other 
amino acids except leucine, supplementation with various leucine concentrations does not 
alter glucose transport rates in L6 myotubes. This may be due to a possible stimulatory 
response in glucose uptake associated with the presence of a combination of amino acids 
rather than just one (ie. leucine).  
     Although the exact mechanisms are unknown, some in-vivo studies suggest that a 
combination of all amino acids may result in greater endogenous insulin secretion and 
greater GLUT4 translocation to the plasma membrane as a result of increased 
phosphorylation of AS160.132,133 AS160 is an inhibitor of GLUT4 translocation, however, 
once phosphorylated by Akt, its inhibitory effect on GLUT4 translocation is removed, 
resulting in the recruitment of GLUT4 from intracellular storage pools to the plasma 
membrane. In addition, a mixture of amino acids that contains isoleucine and arginine has 
been shown to increase glucose uptake levels. 133  
     Furthermore, studies that show amino acid mixtures improve glucose transport have 
worked with concentrations from 2.5 to10 mM which are way beyond physiological 
levels 135. When looking at mTORC1 activation, the availability of other amino acids 
caused a significant stimulation in phosphorylation of S6K1T389 in response to various 
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leucine concentrations. We also observed a dose-dependent but non-significant increase 
in ph-IRS-1Ser612 levels. Moreover, in the presence of other amino acids, basal glucose 
uptake levels were higher compared to control, which is why the magnitude of insulin 
effect was not as strong as the control group. 
     A number of studies have observed elevated levels of BCAAs in obese/insulin-
resistant individuals75,124,126, therefore, it is important to investigate their in-vitro effect in 
skeletal muscle. Since leucine is the strongest BCAA in activating mTORC1 and the 
effects of high protein diets on insulin resistance occur, at least in part through the 
mTORC1/S6K1 pathway, I examined the effect of various concentrations of leucine on 
glucose transport and mTORC1 signalling in skeletal muscle cells. This was to determine 
whether leucine in the absence of other amino acids can regulate glucose transport dose-
dependently. We found that leucine significantly impairs insulin-stimulated glucose 
transport in L6 cells (p<0.05) and this inhibition is particularly more significant at 150 
μM (p<0.01). Interestingly, we observed a more significant reduction in glucose uptake in 
response to 150 μM leucine compared to higher levels. This could possibly be due to a 
dual mechanism associated with leucine’s action such that at lower concentrations (closer 
to physiological levels) it can impair insulin-stimulated glucose uptake, however, as you 
increase the concentration, its effect gradually shifts to a more positive side and 
stimulates glucose uptake due to unknown mechanism. This could be explained by the 
stronger synergistic effect of leucine and insulin at higher leucine concentrations. It may 
also be due to either increased expression of GLUT4 proteins or redistribution of the 
GLUT4 vesicles to the plasma membrane in response to high leucine levels.  
     Moreover, there is some discrepancy between our results and some previous findings 
in the literature. For instance, a recent study by Liu et al. examined the dose-dependent 
effect of leucine on glucose uptake in C2C12 skeletal muscle cells 68. They tested various 
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leucine concentrations (0 to 8 mM) and found that leucine facilitated insulin-stimulated 
glucose uptake, particularly at 2 mM. Nishitani et al. also suggested a stimulatory effect 
of leucine on glucose uptake, particularly at high concentrations (2-3 mM) under insulin-
free conditions 119. However, these studies examined the effect of leucine at 
supraphysiological concentrations which many not be relevant to normal physiological 
conditions. The physiological concentration of leucine in rodents is around 140-150 μM 
17 and in humans it is in the range of 100-150 μM 136–138, therefore, it would not be 
physiologically appropriate to test such high concentrations of leucine (2-8 mM) as these 
studies did. Therefore, results from different studies may vary depending on many factors 
such as experimental procedures and concentration of leucine tested. Thus, further studies 
need to be done to fully elucidate the mechanism of leucine’s action in insulin signalling 
and glucose uptake in skeletal muscle.  
     Interestingly we found that the rate of basal glucose uptake is significantly higher in a 
medium containing all amino acids, compared to one that does not. As mentioned earlier, 
there are certain amino acids in the mixture that can stimulate glucose uptake even in the 
absence of insulin, such as isoleucine and arginine133, therefore, even in the absence of 
insulin, a mixture of amino acids can stimulate glucose transport. 
     Next we determined whether suppression of glucose uptake by leucine occurs via 
mTORC1. We observed a trend for a dose-dependent upregulation in mTORC1 as shown 
by increased phosphorylation of S6K1T389. This is consistent with previous findings in the 
literature showing increased activation of mTORC1 with leucine treatment 22, although no 
studies have examined the dose-dependent effect of leucine on phosphorylation of 
mTORC1 proteins in a physiologically-relevant range. This is an important question 
because the effect of leucine on mTORC1 signalling may be dose-dependent. Serine 
phosphorylation of IRS-1 was also increased in response to leucine treatment, although 
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non-significantly. Thus, our results suggest that leucine promotes mTORC1/S6K1 
activation and increases abnormal IRS-1 function as a result of S6K1-mediated negative 
feedback loop on IRS-1.  
   Next we sought to determine how the first product of leucine’s catabolism (KIC) affects 
glucose uptake and mTORC1 activation. As mentioned before, previous studies have 
shown KIC to be involved in mTORC1 signalling 139, however, its effects on glucose 
transport have not been elucidated. Therefore, we were interested to examine the role of 
KIC in insulin –stimulated glucose transport in L6 cells. Since it is possible that leucine 
exerts its effects through metabolic changes such as its conversion to KIC, we sought to 
examine whether KIC by itself can regulate glucose transport. Our results suggest that 
KIC functions in a similar manner to leucine in glucose transport and mTORC1 
signalling. We observed a significant reduction in insulin-induced glucose uptake with 
200 uM of KIC treatment. Nishitani et. al 119 compared the effect of 2 mM of KIC and 
leucine on glucose uptake in the soleus muscle of rats. They found KIC was able to 
promote glucose uptake at 2 mM, although its effect was weaker than leucine. However, 
once again, they used supraphysiological levels of KIC (1-8 mM), which makes their 
findings questionable and it may not be applicable to normal physiological conditions. 
This is because the physiological concentration of KIC is around 30-35 uM136,137,140, 
therefore, it would not be logical to test such high concentrations of KIC as Nishitani et 
al. did. We also observed an upregulation in ph-S6K1T389 , ph-IRS-1S612 and p-AktS473 
levels which suggest increased mTORC1 activity. Therefore, KIC suppresses insulin-
stimulated glucose transport in L6 myotubes concurrent with increased mTORC1 
activation and therefore, can be implicated in the development of insulin resistance.  
     Since we observed a reduction in insulin-stimulated glucose uptake in response to 200 
uM of KIC and this effect was associated with increased mTORC1 activity, we were 
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interested to determine if the effects were specifically mTORC1-dependent. Because in 
our previous experiment, 200 uM of KIC treatment caused a more significant reduction in 
insulin-induced glucose uptake, we chose 200 uM as our testing concentration in this 
experiment. As observed before, KIC significantly suppressed insulin-mediated glucose 
uptake (p<0.05). Interestingly, the addition of rapamycin to KIC ameliorated the 
inhibitory effect of KIC on glucose transport (p<0.05), indicting the specific involvement 
of mTORC1 in KIC-mediated regulation of glucose transport. We next examined the 
effect of KIC and rapamycin on KIC-mediated regulation of mTORC1 activation. Co-
incubation of KIC with rapamycin, suppressed the KIC-induced phosphorylation of IRS-
1Ser612, S6K1T389 and S6Ser235/236, indicating that the effect of KIC on insulin signalling is 
mTORC1-dependent. In the presence of KIC and rapamycin, ph-S6k1T389 levels were not 
detectable at all. This could possibly be due to the specifically strong inhibition of 
rapamycin on phosphorylation of S6K1 such that even the presence of insulin and KIC 
was not sufficient to activate S6K1.  
     Our next question was to determine whether KIC can by itself regulate glucose 
transport and mTORC1 signalling in L6 myotubes, or if the effects we observed are due 
to the intracellular conversion of KIC to leucine. This is because the first step in leucine 
metabolism, catalyzed by the BCAT2 enzyme, is reversible and KIC can be converted 
back to leucine intracellularly. When we knocked down the BCAT2 enzyme and 
supplemented the cells with KIC, we found that in the scramble condition (control), KIC 
suppressed insulin-stimulated glucose transport as expected; however, in the knockdown 
condition, KIC-mediated suppression of insulin-induced glucose transport was abolished.         
To our knowledge, the effect of the BCAT2 enzyme in KIC-mediated regulation of 
glucose transport in L6 skeletal muscle cells has not been studied. She et al. examined the 
effect of whole body BCAT2 knockout in mice and found that disruption of BCAT2 
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leads to improved insulin sensitivity in mice despite elevated BCAA levels, indicating an 
important role for BCAT2 in the development of insulin resistance and T2DM 66. Our 
results indicate that negative effects associated with KIC treatment on insulin-stimulated 
glucose transport are due to the intracellular conversion of KIC to leucine and that in fact, 
it is leucine which impairs insulin signalling.  
     Finally, we probed the effect of BCAT2 knockdown on KIC-mediated regulation of 
mTORC1 signalling. Unfortunately, we did not observe a strong stimulation of ph-
S6K1T389 and ph-IRS-1S612 levels in response to KIC treatment in our scramble condition. 
This could be due to the high level of cell death and cell toxicity associated with siRNA 
gene silencing which could diminish or mask the effect of KIC on activation of 
mTORC1. However, interestingly, we found that BCAT2 knockdown significantly 
suppresses KIC-mediated mTORC1 activation as shown by ph-S6K1T389 and ph-IRS-
1S612 levels in the knockdown condition. These results further support our findings that 
KIC-mediated regulation of glucose transport and mTORC1/S6K1 activation occur 
through the reversible conversion of KIC to leucine. Therefore, targeting this enzyme 
could be a new therapeutic approach in the treatment of insulin resistance and T2DM.  
     In conclusion, my results demonstrate that leucine can impair insulin-stimulated 
glucose transport in skeletal muscle through a negative feedback mechanism involving 
increased mTORC1/S6K1 activation which leads to insulin resistance. The inhibitory 
effect of leucine on glucose transport disappears in a mixture of other amino acids, 
possibly due to the presence of amino acids such as isoleucine and arginine which 
stimulate glucose uptake. Similar to leucine, its metabolite, KIC can also impair insulin-
induced glucose transport concurrent with increased mTORC1 activation in rat skeletal 
muscle cells. Our novel findings indicate that diminishing the activity of the BCAT2 
enzyme reverses the KIC-mediated suppression of glucose transport, supporting the 
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notion that KIC exerts its effects through its intracellular conversion to leucine. This 
indicates that altering BCAA metabolism may be a new strategy in certain pathological 
conditions such as T2DM. Even though BCAA supplementation may be beneficial in 
overweight/obese individuals for weight management, excess levels could lead to the 
development of insulin resistance via persistent mTORC1 activation and loss of normal 
IRS-1 function.  
     Some of the limitations of my study include the lack of examining total protein levels 
of S6K1, IRS-1 and Akt. However, since the measures we were interested in examining 
were not likely to modulate total protein levels, we used gamma tubulin as our loading 
control to normalize our protein levels. Furthermore, to determine whether leucine-
mediated regulation of glucose transport is completely mTORC1 dependent, I could have 
used the mTORC1 inhibitor, rapamycin in my treatments. This would allow us to find out 
if leucine-mediated regulation of glucose uptake involves other mechanisms. Also, to 
further support our findings in the BCAT2 experiments, we could have used other 
methods to abolish the activity of the enzyme, such as specific inhibitor of BCAT2.  
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9.0 Future Directions 
Even though my results have shown some novel findings with regards to the effect of 
KIC on glucose transport and mTORC1 activation, further studies are needed to fully 
examine KIC-mediated regulation of insulin signalling. Some future work could include:    
 
1. Knocking down the BCAT2 enzyme and supplementing the cells with leucine to 
confirm our findings that leucine and not its metabolite, mediates the negative 
effects observed with glucose transport and mTORC1 activation 
2. Examining the role of another downstream metabolite of leucine (HMB) on 
glucose transport and mTORC1 signalling and comparing its effect to KIC. This 
is because HMB has been shown to stimulate protein synthesis via mTORC1 and 
therefore, could possibly be implicated in insulin resistance and T2DM. 
2. Examining the effect of markers of inflammation on leucine/KIC regulation of 
glucose transport since inflammation can lead to the development of insulin resistance  
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11.0 Appendix 
 
 
 
 
A) Experiment Outline: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Myotubes were starved for 4h in serum and amino acid-free medium. They were then 
incubated in an amino acid-free medium to which leucine was added at various 
concentrations for 30 minutes. Following this, the cells were incubated with or without 
insulin for 20 minutes and harvested for either western blot analysis or glucose transport 
assay.  
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B) Glucose Transport Assay 
 
 
Solutions 
 
Hepes Buffer Saline:  
• 140 mM NaCl 
• 20 mM Hepes-Na, pH 7.4 
• 5 mM KCl 
• 2.5 mM MgSO4  
• 1.0 mM CaCl2 
 
Stop Solution:  
• 0.9% NaCl (Saline) 
 
2-DG Stock Solution: 
• 10 mM 2-Deoxy-D-Glucose in Hepes buffer 
 
Transport Solution (TS): 
• Prepare in Hepes buffer 
• 10 µM 2-Dexocy-Glucose 
• 0.5 µCi/mL 3H 2-Deoxy-Glucose 
 
 
Procedures  
 
1. On the designated radioactive bench in the lab, wash cells two times with Hepes 
Buffered Saline (HBS) at room temperature and aspirate any remaining buffer 
2. Add 300 µl of of Transport Solution (TS) per well for a 12-well plate.  
3. Incubate the plates for 5 minutes at 37°. Be sure to not exceed this time.  
4. Aspirate away the Transport Solution (TS) quickly and wash the wells thoroughly 
three times with ice-cold Stop Solution (0.9% Saline). Aspirate to dryness. 
5. While on ice, add 1.0 mL of 0.05N NaOH to each well in the plate.  
6. Scrape the cells and transfer 0.8 mL of the contents into plastic Scintillation vials 
already filled with 4-5 mL of Scintillation fluid.  
7. Transfer the remaining contents into 1.5 mL Eppendorf tubes (to be used for 
protein assay).  
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8. Count the amount of radioactivity in each vial using the Scintillation counter and 
measure the amount of radioactivity in each sample.  
 
C) RNAi Gene Silencing 
 
 
Materials 
• Opti-MEM (Life technologies: cat # 31985-070) 
• Lipofectamine RNAiMAX reagent (Life technologies: cat #13778-150) 
• siRNA scramble and BCAT2 (Sigma Aldrich) 
• Growth Medium (GM) without antibiotics (AMEM (Wisent Inc. Cat # 310-010-
CL) supplemented with 10% FBS (Cat # 12484-028)) 
• Growth Medium (GM) with antibiotics (AMEM (Wisent Inc. Cat # 310-010-CL) 
supplemented with 10% FBS (Cat # 12484-028) and 1% Ab-Am (Wisent Inc. Cat 
# 450-115-EL)) 
• 15 ml polypropylene conical tubes (BD Falcon Ref #372096) 
• 6 well plates (Cellstar: cat # 657160) 
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Procedures:  
1. In the cell culture hood, prepare three 15 ml tubes and label as Optimum, “A”, 
“B” and “C”  
   A Lipofectamine+ Opti-MEM 
   B BCAT2 siRNA+Opti-MEM 
         C Scramble siRNA+Opti-MEM 
2. Pour Optimum solution into the designated 15 ml-Optimum tube (without 
touching the mouth of the bottle). 
3. Add 120 µl of Opti-MEM +5 µl of Lipofectamine to tube “A”. 
4. Add 2-3 µl of BCAT2 siRNA and 122-123 µl of Opti-MEM to tube “B”. 
5. Add 2-3 µl of scramble siRNA and 122-123 µl of Opti-MEM to tube “C”. 
6. Add mix “A” to mix “B” in 1:1 ratio. (For example, 125 µl of “A” + 125 µl of 
“B”.  
7. Wait at least 5 minutes. 
8. While waiting, add 1 mL/well of GM without antibiotics, and add cells to each 
well. 
9. Add 250 µl/well of diluted mixture to each well. 
10. Following 24 hours, add 1 mL/well of GM (with antibiotics). 
 
 
 
 
 
 
 
 
